Guided Therapeutics (GTHP) 10-Q 18 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 10, 2021
Cover [Abstract]
Entity Registrant Name	GUIDED THERAPEUTICS, INC.
Entity Central Index Key	0000924515
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		13,296,880
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity File Number	0-22179
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	58-2029543
Entity Address Address Line 1	5835 Peachtree Corners East
Entity Address Address Line 2	Suite D
Entity Address City Or Town	Norcross
Entity Address State Or Province	GA
Entity Address Postal Zip Code	30092
City Area Code	770
Local Phone Number	242-8723

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 922,000	$ 182,000
Accounts receivable, net of allowance for doubtful accounts of $126 at June 30, 2021 and December 31, 2020	26,000	24,000
Inventory, net of reserves of $758 at June 30, 2021 and December 31, 2020	631,000	605,000
Other current assets	61,000	85,000
Total current assets	1,640,000	896,000
NONCURRENT ASSETS:
Property and equipment, net	7,000	1,000
Lease asset-right, net of amortization	403,000	453,000
Other assets	17,000	0
Total noncurrent assets	427,000	454,000
TOTAL ASSETS	2,067,000	1,350,000
CURRENT LIABILITIES:
Current portion of long-term debt	24,000	28,000
Notes payable in default, related parties	0	1,000
Notes payable in default	308,000	328,000
Short-term notes payable	0	45,000
Short-term notes payable, related parties, past due	65,000	51,000
Convertible notes in default	169,000	0
Convertible notes payable, past due	0	1,930,000
Short-term convertible notes payable	720,000	951,000
Accounts payable	2,383,000	2,419,000
Accounts payable, related parties	97,000	116,000
Accrued liabilities	1,731,000	2,995,000
Mandatorily redeemable Series G convertible preferred stock	50,000	0
Current portion of lease liability	62,000	56,000
Deferred revenue	62,000	42,000
Total current liabilities	5,671,000	8,962,000
LONG-TERM LIABILITIES:
Warrants, at fair value	0	2,203,000
Lease liability	357,000	392,000
Derivative liability	29,000	25,000
Long-term convertible debt	755,000	23,000
Long-term debt-related parties	579,000	600,000
Total long-term liabilities	1,720,000	3,243,000
TOTAL LIABILITIES	7,391,000	12,205,000
STOCKHOLDERS' DEFICIT:
Common stock, $.001 par value; 3,000,000 shares authorized, 13,297 and 13,138 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	3,403,000	3,403,000
Additional paid-in capital	126,353,000	123,109,000
Treasury stock, at cost	(132,000)	(132,000)
Accumulated deficit	(141,827,000)	(139,956,000)
TOTAL STOCKHOLDERS' DEFICIT	(5,324,000)	(10,855,000)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	2,067,000	1,350,000
Series C Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	105,000	105,000
Series C1 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	170,000	170,000
Series C2 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	531,000	531,000
Series D Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	276,000	276,000
Series E Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	1,639,000	1,639,000
Series F Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	1,195,000	0
Series F-2 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	2,963,000	0
Series G Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred Stock Value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
CURRENT ASSETS:
Accounts receivable, net of allowance	$ 126,000	$ 126,000
Inventory, net of reserves	$ 758,000	$ 758,000
STOCKHOLDERS' DEFICIT:
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	3,000,000	3,000,000
Common stock, issued	13,297	13,138
Common stock, outstanding	13,297	13,138
Preferred stock, par value	$ 0.001
Preferred stock, authorized	5,000,000
Series C Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	9	9
Preferred stock, liquidation preference	$ 286	$ 286
Preferred stock, outstanding	286
Series D Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	6	6
Preferred stock, liquidation preference	$ 763	$ 763
Series E Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5	5
Preferred stock, liquidation preference	$ 1,736	$ 1,736
Series F Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation preference	$ 1,421	$ 1,421
Series G Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	1,000	1,000
Preferred stock, liquidation preference	$ 62	$ 0
Preferred stock, issued	62	0
Preferred stock, outstanding	0	0
Series C-1 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation preference	$ 1,049	$ 1,049
Preferred stock, issued	1	1
Preferred stock, outstanding	1	1
Series C-2 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000	5,000
Preferred stock, liquidation preference	$ 3,263	$ 3,263
Series F-2 Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5	5
Preferred stock, liquidation preference	$ 3,339	$ 3,339
Preferred stock, issued	3,237
Preferred stock, outstanding	3,237

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
REVENUE:
Sales - devices and disposables	$ 2,000	$ 0	$ 2,000	$ 0
Cost of goods sold	0	6,000	0	6,000
Gross profit (loss)	2,000	(6,000)	2,000	(6,000)
OPERATING EXPENSES:
Research and development	20,000	55,000	36,000	80,000
Sales and marketing	30,000	37,000	66,000	71,000
General and administrative	513,000	271,000	1,340,000	453,000
Total operating expenses	563,000	363,000	1,442,000	604,000
Operating loss	(561,000)	(369,000)	(1,440,000)	(610,000)
OTHER INCOME (EXPENSES):
Other income	27,000	50,000	27,000	51,000
Interest expense	(315,000)	(308,000)	(456,000)	(594,000)
Change in fair value of derivative liability	0	0	(88,000)	0
(Loss) gain from extinguishment of debt	(185,000)	(343,000)	(185,000)	(316,000)
Change in fair value of warrants	0	(5,779,000)	448,000	(2,551,000)
Total other income (expenses)	(473,000)	(6,380,000)	(254,000)	(3,410,000)
LOSS BEFORE INCOME TAXES	(1,034,000)	(6,749,000)	(1,694,000)	(4,020,000)
PROVISION FOR INCOME TAXES	0	0	0	0
NET LOSS	(1,034,000)	(6,765,000)	(1,694,000)	(4,049,000)
PREFERRED STOCK DIVIDENDS	(125,000)	(17,000)	(177,000)	(29,000)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (1,159,000)	$ (6,766,000)	$ (1,871,000)	$ (4,049,000)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
BASIC	$ (0.09)	$ (0.57)	$ (0.14)	$ (0.48)
DILUTED	$ (0.09)	$ (0.57)	$ (0.14)	$ (0.48)
WEIGHTED AVERAGE SHARES OUTSTANDING
WEIGHTED AVERAGE SHARES OUTSTANDING BASIC	13,280	11,913	13,226	8,463
WEIGHTED AVERAGE SHARES OUTSTANDING DILUTED	13,280	11,913	13,226	8,463

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Total	Preferred Stock Series C [Member]	Preferred Stock Series C1 [Member]	Preferred Stock Series C2 [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Preferred Stock Series F [Member]	Preferred Stock Series F-2 [Member]	Preferred Stock Series G [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]
Balance, shares at Dec. 31, 2019			1,000	3,000						3,319,000
Balance, amount at Dec. 31, 2019	$ (16,935,000)	$ 105,000	$ 170,000	$ 531,000	$ 0	$ 0	$ 0	$ 0	$ 0	$ 3,394,000	$ 118,552,000	$ (132,000)	$ (139,555,000)
Issuance of preferred stock in financing	1,616,000							0	0	$ 0	487,000	0	0
Issuance of preferred stock in financing, shares					1,000	1,000
Conversion of debt into common stock, shares										7,957,000
Issuance of preferred stock in financing, amount		0	0	0	$ 276,000	$ 853,000	0
Conversion of debt into common stock, amount	2,700,000							0	0	$ 8,000	2,692,000	0	0
Conversion of debt into common stock		0	0	0	0	0	0
Issuance of common stock in financing, shares										1,476,000
Issuance of common stock in financing		0	0	0	0	0	0
Issuance of common stock in financing, amount	178,000							0	0	$ 1,000	177,000	0	0
Issuance of warrants in financing	67,000	0	0	0	0	0	0	0	0	$ 0	67,000	0	0
Issuance of common stock for manufacturing agreements		0	0	0	0	0	0
Issuance of common stock for manufacturing agreements, shares										13,000
Issuance of common stock for manufacturing agreements, amount	0							0	0	$ 0	0	0	0
Accrued preferred dividends	0	0	0	0	0	0	0	0	0	0	0	0	0
Net loss	(4,049,000)	0	$ 0	$ 0	$ 0	$ 0	0	0	0	$ 0	0	0	(4,049,000)
Balance, shares at Jun. 30, 2020			1,000	3,000	1,000	1,000				12,765,000
Balance, amount at Jun. 30, 2020	(16,423,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 853,000	0	0	0	$ 3,403,000	121,975,000	(132,000)	(143,604,000)
Balance, shares at Dec. 31, 2019			1,000	3,000						3,319,000
Balance, amount at Dec. 31, 2019	$ (16,935,000)	105,000	$ 170,000	$ 531,000	$ 0	$ 0	0	0	0	$ 3,394,000	118,552,000	(132,000)	(139,555,000)
Balance, shares at Dec. 31, 2020	13,138,282		1,000	3,000	1,000	2,000				13,138,000
Balance, amount at Dec. 31, 2020	$ (10,855,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	0	0	0	$ 3,403,000	123,109,000	(132,000)	(139,956,000)
Balance, shares at Mar. 31, 2020			1,000	3,000	1,000					11,765,000
Balance, amount at Mar. 31, 2020	(11,345,000)	105,000	$ 170,000	$ 531,000	$ 268,000	$ 0	0	0	0	$ 3,402,000	121,150,000	(132,000)	(136,839,000)
Issuance of preferred stock in financing	1,062,000							0	0	$ 0	487,000	0	0
Issuance of preferred stock in financing, shares						1,000
Conversion of debt into common stock, shares										1,000,000
Issuance of preferred stock in financing, amount		0	0	0	8,000	$ 853,000	0
Conversion of debt into common stock, amount	625,000							0	0	$ 1,000	624,000	0	0
Conversion of debt into common stock		0	0	0	0	0	0
Net loss	(6,765,000)	0	$ 0	$ 0	$ 0	$ 0	0	0	0	$ 0	0	0	(6,765,000)
Balance, shares at Jun. 30, 2020			1,000	3,000	1,000	1,000				12,765,000
Balance, amount at Jun. 30, 2020	$ (16,423,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 853,000	0	0	0	$ 3,403,000	121,975,000	(132,000)	(143,604,000)
Balance, shares at Dec. 31, 2020	13,138,282		1,000	3,000	1,000	2,000				13,138,000
Balance, amount at Dec. 31, 2020	$ (10,855,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	0	0	0	$ 3,403,000	123,109,000	(132,000)	(139,956,000)
Accrued preferred dividends	(177,000)	0	0	0	0	0	0	0	0	0	0	0	(177,000)
Net loss	(1,694,000)	0	0	0	0	0	0	0	0	0	0	0	(1,694,000)
Series D preferred offering	0	0	0	0	0	0	0	0	0	0	0	0	0
Series E preferred offering	0	0	0	0	0	0	$ 0	0	0	0	0	0	0
Series F preferred offering, shares							1,000
Series F preferred offering, amount		0	0	0	0	0	$ 1,195,000
Series F preferred offering	1,195,000							$ 0	0	0	0	0	0
Series F-2 preferred offering		0	0	0	0	0	0
Series F-2 preferred offering, shares								1,000
Series F-2 preferred offering, amount	404,000							$ 404,000	0	0	0	0	0
Conversion of debt and expenses for Series F-2 preferred stock		0	0	0	0	0	0
Conversion of debt and expenses for Series F-2 preferred stock, shares								2,000
Issuance of warrants to finders		0	0	0	0	0	0
Conversion of debt and expenses for Series F-2 preferred stock, amount	2,559,000							$ 2,559,000	0	$ 0	0	0	0
Series G preferred offering		0	0	0	0	0	0
Issuance of common stock to finders, shares										98,000
Series G redemption		0	0	0	0	0	0
Issuance of common stock to finders, amount	54,000							0	$ 0	$ 0	54,000	0	0
Issuance of common stock for payment of Series D preferred dividends		0	0	0	0	0	0
Series G preferred offering, shares									153,000
Series G preferred offering, amount	0							0	$ 0	0	0	0	0
Issuance of warrants to consultants		0	0	0	0	0	0
Series G redemption, shares									(91,000)
Conversion of warrants from liability to equity	1,755,000	0	0	0	0	0	0	0	$ 0	0	1,755,000	0	0
Series G redemption, amount	0							0	0	0	0	0	0
Stock-based compensation	122,000	0	$ 0	$ 0	$ 0	$ 0	$ 0	0	0	$ 0	122,000	0	0
Issuance of common stock for payment of Series D preferred dividends, shares										61,000
Issuance of common stock for payment of Series D preferred dividends, amount	28,000							0	0	$ 0	28,000	0	0
Issuance of warrants to consultants	$ 1,285,000							$ 0	$ 0	$ 0	1,285,000	0	0
Balance, shares at Jun. 30, 2021	13,296,880		1,000	3,000	1,000	2,000	1,000	3,000	62,000	13,297,000
Balance, amount at Jun. 30, 2021	$ (5,324,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 1,195,000	$ 2,963,000	$ 0	$ 3,403,000	126,353,000	(132,000)	(141,827,000)
Balance, shares at Mar. 31, 2021	13,180,417		1,000	3,000	1,000	2,000	1,000
Balance, amount at Mar. 31, 2021		105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 1,195,000
Accrued preferred dividends	$ (125,000)	0	0	0	0	0	0						(125,000)
Net loss	(1,034,000)	0	0	0	0	0	0						(1,034,000)
Series D preferred offering	0	0	0	0	0	0	0	0	0	0	0	0	0
Series E preferred offering		0	0	0	0	0	0	0	$ 0	$ 0	0	0	0
Series F-2 preferred offering	404,000	0	0	0	0	0	0	$ 404,000
Conversion of debt and expenses for Series F-2 preferred stock		0	0	0	0	0	0
Conversion of debt and expenses for Series F-2 preferred stock, shares								3,000
Issuance of warrants to finders		0	0	0	0	0	0
Conversion of debt and expenses for Series F-2 preferred stock, amount	2,559,000							$ 2,559,000
Series G preferred offering		0	0	0	0	0	0
Issuance of common stock to finders, shares										98,000
Series G redemption		0	0	0	0	0	0
Issuance of common stock to finders, amount	54,000										54,000
Issuance of common stock for payment of Series D preferred dividends		0	0	0	0	0	0
Series G redemption, shares									(91,000)
Conversion of warrants from liability to equity		0	0	0	0	0	0
Stock-based compensation	60,000	0	0	0	0	0	0				60,000
Issuance of common stock for payment of Series D preferred dividends, shares										19,000
Issuance of common stock for payment of Series D preferred dividends, amount	14,000										14,000
Issuance of warrants to consultants	$ 736,000	0	$ 0	$ 0	$ 0	$ 0	$ 0				736,000
Balance, shares at Jun. 30, 2021	13,296,880		1,000	3,000	1,000	2,000	1,000	3,000	62,000	13,297,000
Balance, amount at Jun. 30, 2021	$ (5,324,000)	$ 105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 1,195,000	$ 2,963,000	$ 0	$ 3,403,000	$ 126,353,000	$ (132,000)	$ (141,827,000)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,694,000)	$ (4,020,000)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Bad debt expense	0	13,000
Amortization of debt issuance costs and discounts	236,000	194,000
Amortization of beneficial conversion feature	8,000	53,000
Stock-based compensation	122,000	0
Change in fair value of warrants	(448,000)	2,551,000
Warrants issued for consulting services	477,000	0
(Gain) loss from extinguishment of debt	185,000	316,000
Change in fair value of derivative liability	(88,000)	0
Changes in operating assets and liabilities:
Accounts receivable	(2,000)	0
Inventory	(26,000)	(3,000)
Other current assets	24,000	29,000
Other assets	(17,000)	(18,000)
Accounts payable	(55,000)	19,000
Deferred revenue	20,000	0
Accrued liabilities	70,000	(108,000)
Total adjustments	682,000	3,082,000
Net cash used in operating activities	(1,012,000)	(938,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to fixed assets	(5,000)	(1,000)
Net cash used in investing activities	(5,000)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from debt financing, net of discounts and debt issuance costs	1,044,000	519,000
Proceeds from issuance of Series E Preferred Stock	0	853,000
Proceeds from Series F offering, net of costs	1,436,000	0
Proceeds from Series F-2 offering, net of costs	539,000	0
Proceeds from Series G offering, net of costs	125,000	0
Note payable default penalty	56,000	0
Redemption of Series G Preferred Stock	(75,000)	0
Payments on notes and loans payable	(1,368,000)	(697,000)
Proceeds from the issuance of common stock	0	128,000
Net cash provided by financing activities	1,757,000	803,000
NET CHANGE IN CASH AND CASH EQUIVALENTS	740,000	(136,000)
CASH AND CASH EQUIVALENTS, beginning of year	182,000	899,000
CASH AND CASH EQUIVALENTS, end of period	922,000	763,000
Cash paid for:
Interest	541,000	209,000
NONCASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock as debt repayment	0	2,529,000
Issuance of Series F-2 preferred stock	2,559,000	0
Issuance of warrants to finders in connection with Series F and Series F-2 preferred stock	377,000	0
Dividends on preferred stock	177,000	29,000
Subscription receivable	0	635,000
Settlement of dividends through common stock issuance	31,000	0
Settlement of accounts payable through common stock issuance	24,000	0
Warrants exchanged for fixed price warrants	$ 1,755,000	$ 67,000

ORGANIZATION, BACKGROUND, AND B

ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2021
ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION
1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION	1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers. Basis of Presentation All information and footnote disclosures included in the consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. In the opinion of management, all adjustments (consisting of normal recurring accruals and other items) considered necessary for a fair presentation have been included. The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of June 30, 2021, it had an accumulated deficit of approximately $141.8 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development. Going Concern The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. At June 30, 2021, the Company had a negative working capital of approximately $4.0 million, accumulated deficit of $141.8 million, and incurred a net loss including preferred dividends of $1.9 million for the six months then ended. Stockholders’ deficit totaled approximately $5.3 million at June 30, 2021, primarily due to recurring net losses from operations. During 2021, the Company did raise $2.1 million as part of the Series F, Series F-2 and G preferred stock capital raise and $1.1 million for 10% convertible debentures. The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised during 2021, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection. The Company had warrants exercisable for approximately 30.1 million shares of its common stock outstanding at June 30, 2021, with exercise prices ranging between $0.15 and $0.80 per share. Exercises of in the money warrants would generate a total of approximately $5.7 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2021
SIGNIFICANT ACCOUNTING POLICIES
2. SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Guided Therapeutics, Inc. and its wholly owned subsidiary. All intercompany transactions are eliminated. Accounting Standard Updates In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740)”. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and by clarifying and amending other areas of Topic 740. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2020. We adopted this ASU on January 1, 2021 with no material impact on our consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders’ equity to liabilities as it relates to the Company’s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS), which is consistent with the Company’s accounting treatment under the current standard. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. The Company has early adopted ASU No. 2020-06 under a modified retrospective basis on January 1, 2021. The result of the early adoption would have been a change to retained earnings of $102,000 for the year ended December 31, 2020. Except as noted above, the guidance issued by the FASB during the current year is not expected to have a material effect on the Company’s consolidated financial statements. A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent. Accounts Receivable The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility, is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable. Concentrations of Credit Risk The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk. Inventory Valuation All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. At June 30, 2021 and December 31, 2020, our inventories were as follows (in thousands): June 30, December 31, 2021 2020 Raw materials $ 1,286 $ 1,276 Work in process 81 80 Finished goods 22 7 Inventory reserve (758 ) (758 ) Total $ 631 $ 605 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at June 30, 2021 and December 31, 2020 (in thousands): June 30, December 31, 2021 2020 Equipment $ 1,048 $ 1,042 Software 652 652 Furniture and fixtures 41 41 Leasehold improvement 12 12 1,753 1,747 Less accumulated depreciation and amortization (1,746 ) (1,746 ) Total $ 7 $ 1 During the six months ended June 30, 2021 and year ended December 31, 2020, the Company disposed of approximately nil and $647,000 of property and equipment that was fully depreciated, respectively. Debt Issuance Costs Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount. Patent Costs (Principally Legal Fees) Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs aggregated approximately $10,000 and $4,000 for the six months ended June 30, 2021 and 2020, respectively. Leases With the implementation of ASU 2016-02, “Leases (Topic 842)”, the Company recorded a lease-right-of-use asset and a lease liability. The Company adopted the standard on January 1, 2019. The implementation required the analysis of certain criteria in determining its treatment. The Company determined that its corporate office lease met those criteria. The Company implemented the guidance using the alternative transition method. Under this alternative, the effective date would be the date of initial application. See Note 7: Commitments and Contingencies Accrued Liabilities Accrued liabilities are summarized as follows (in thousands): June 30, 2021 December 31, 2020 Compensation $ 781 $ 1,094 Professional fees 28 83 Subscription receivable 350 - Interest 138 1,517 Vacation 43 34 Preferred dividends 347 202 Other accrued expenses 44 65 Total $ 1,731 $ 2,995 Subscription receivables Cash received from investors for common stock shares that has not completed processing is recorded as a liability to subscription receivables. As of June 30, 2021, the Company had received $350,000 from Mr. Blumberg. Revenue Recognition The Company follows, ASC 606 Revenue from Contracts with Customers establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and, the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company had $2,000 and nil in revenues for the six months ended June 30, 2021 and 2020. Significant Distributors As of June 30, 2021, accounts receivable outstanding was $152,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $26,000 which was from two distributors. As of December 31, 2020, accounts receivable outstanding was $150,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $24,000 which was from one distributor. Deferred revenue The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of June 30, 2021, and December 31, 2020, the Company had $62,000 and $42,000in deferred revenue, respectively. Research and Development Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred. Income Taxes The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management provides valuation allowances against the deferred tax assets for amounts that are not considered more likely than not to be realized. The Company has filed its 2020 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At December 31, 2020, the Company has approximately $61.6 million of net operating losses carryforward available. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The current corporate tax rate in the U.S. is 21%. Uncertain Tax Positions The Company assesses each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At December 31, 2020 and, 2019, there were no uncertain tax positions. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Warrants The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model. Stock Based Compensation The Company records compensation expense related to options granted to employees and non-employees based on the fair value of the award. Compensation cost is recorded as earned for all unvested stock options outstanding at the beginning of the first year based upon the grant date fair value estimates, and for compensation cost for all stock based payments granted or modified subsequently based on fair value estimates. On July 14, 2020, the Company granted stock options to employees and consultants. The new Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. Stock options granted have a 10-year life and expire 90 days after employment or upon termination of consulting agreement. Vesting schedule varies per grantee. Generally stock options granted vest as follows: 25% vest immediately, and the remaining stock options vest over 33 months, beginning three months after grant. For the six months ended June 30, 2021 and 2020 share-based compensation for options attributable to employees, non-employees, officers and Board members were approximately $122,000 and nil, respectively. These amounts have been included in the Company’s statements of operations under general and administrative expense. Compensation costs for stock options which vest over time are recognized over the vesting period. As of June 30, 2021, and 2020 the Company had approximately $450,000 and nil of unrecognized compensation costs related to granted stock options that will be recognized, respectively. Beneficial Conversion Features of Convertible Securities The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of January 1, 2020. In doing so, warrants with a down round feature previously treated as a derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Conversion options that are not bifurcated as a derivative pursuant to ASC 815 and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether they are beneficial to the investor at inception (a beneficial conversion feature) or may become beneficial in the future due to potential adjustments. The beneficial conversion feature guidance in ASC 470-20 applies to convertible stock as well as convertible debt which are outside the scope of ASC 815. A beneficial conversion feature is defined as a nondetachable conversion feature that is in the money at the commitment date. The beneficial conversion feature guidance requires recognition of the conversion option’s in-the-money portion, the intrinsic value of the option, in equity, with an offsetting reduction to the carrying amount of the instrument. The resulting discount is amortized as a dividend over either the life of the instrument, if a stated maturity date exists, or to the earliest conversion date, if there is no stated maturity date. If the earliest conversion date is immediately upon issuance, the dividend must be recognized at inception. When there is a subsequent change to the conversion ratio based on a future occurrence, the new conversion price may trigger the recognition of an additional beneficial conversion feature on occurrence. The Company also adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Derivatives The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2021
FAIR VALUE OF FINANCIAL INSTRUMENTS
3. FAIR VALUE OF FINANCIAL INSTRUMENTS	3. FAIR VALUE OF FINANCIAL INSTRUMENTS The guidance for fair value measurements, ASC820, Fair Value Measurements and Disclosures, establishes the authoritative definition of fair value, sets out a framework for measuring fair value, and outlines the required disclosures regarding fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy based upon observable and non-observable inputs as follow: · Level 1–Quoted market prices in active markets for identical assets and liabilities; · Level 2–Inputs, other than level 1 inputs, either directly or indirectly observable; and · Level 3–Unobservable inputs developed using internal estimates and assumptions (there is little or no market date) which reflect those that market participants would use. The Company records its derivative activities at fair value. As of June 30, 2021 we had one instrument that we valued for the derivative liability associated with the bifurcated conversion option of the Auctus loan for $400,000 ($700,000 of the $1,100,000 was paid in the three months ended June 30, 2021). Warrants were valued at December 31, 2020. The fair value of the warrants was estimated using the Binomial Simulation model. Gains and losses from derivative contracts are included in the change in fair value of the derivative liability in the statement of operations. The fair value of the Company’s derivative warrants is classified as a Level 3 measurement, since unobservable inputs are used in the valuation. The following table presents the fair value for those liabilities measured on a recurring basis as of June 30, 2021 and December 31, 2020: FAIR VALUE MEASUREMENTS (In Thousands) The following is summary of items that the Company measures at fair value on a recurring basis: Fair Value at June 30, 2021 Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 - - (29 ) (29 ) Total long-term liabilities at fair value $ - $ - $ (29 ) $ (29 ) Fair Value at December 31, 2020 Level 1 Level 2 Level 3 Total Warrants issued in connection with Senior Secured Debt - - (2,203 ) (2,203 ) Derivative liability/bifurcated conversion option in connection with Auctus $1,100,000 loan on December 17, 2019 - - (25 ) (25 ) Total long-term liabilities at fair value $ - $ - $ (2,228 ) $ (2,228 ) The following is a summary of changes to Level 3 instruments during the six months ended June 30, 2021: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Senior Secured Debt Derivative Total Balance, December 31, 2020 $ (2,203 ) $ (25 ) $ (2,228 ) Change in the terms of warrants previously recorded as a liability and now reclassified to equity 1,755 - 1,755 Change in value due to warrants expiring during the year 448 - 448 Extinguishment of derivative liability due to payoff of $700,000 loan to Auctus 84 84 Change in fair value during the year - (88 ) (88 ) Balance, June 30, 2021 $ - $ (29 ) $ (29 ) As of June 30, 2021, the fair value of warrants was approximately nil and the fair value of the derivative liability was approximately $29,000. A net change of approximately $2.2 million has been recorded to the accompanying statement of operations for the six months ended June 30, 2021. As of December 31, 2020, the fair value of warrants was approximately $2.2 million and the fair value of the derivative liability was $25,000.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	6 Months Ended
	Jun. 30, 2021
STOCKHOLDERS' DEFICIT:
4. STOCKHOLDERS' DEFICIT	4. STOCKHOLDERS’ DEFICIT Common Stock The Company has authorized 3,000,000,000 shares of common stock with $0.001 par value, of which 13,296,880 were issued and outstanding as of June 30, 2021. As of December 31, 2020, there were 3,000,000,000 authorized shares of common stock, of which 13,138,282 were issued and outstanding. For the six months ended June 30, 2021, the Company issued 158,598 shares of common stock as listed below: Shares issued for payments of Series D dividends 60,598 Shares issued for payment of finder fee 98,000 Issued during the six months ended June 30, 2021 158,598 Summary table of common stock share transactions: Balance at December 31, 2020 13,138,282 Issued in 2021 158,598 Balance at June 30, 2021 13,296,880 Investments During 2021, the Company received 10% debenture unit investments in the amount of $1,130,000 and incurred fees due on these debentures of $86,400. The Company also issued the finders 413,600 warrants for the Company’s common stock shares. These investors received a total of 1,130,000 warrants for common stock shares. The debentures are convertible into 2,260,000 of the Company’s common stock shares. During 2021, the Company received equity investments in the amount of $2,114,000 and incurred fees due on these investments of $139,000. The Company also issued the finders 98,000 of the Company’s common stock shares and 643,700 warrants for the Company’s common stock shares. These investors received a total of 2,114 Series F and Series F-2 preferred stock (if the Investor elects to convert their Series F or Series F-2 preferred stock, each Series F or Series F-2 preferred stock shares converts into 4,000 shares of the Company’s common stock shares). During 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $132,000, net to the Company is $125,000, for 153,000 shares of Series G preferred stock. As of June 30, 2021, 91,000 of the Series G preferred stock was redeemed and the Company has a remaining balance of 62,000 Series G preferred stock. During 2020, the Company received equity investments in the amount of $1,735,500 and incurred fees due on these investments of $96,985. The Company also issued the finders 67,000 warrants for the Company’s common stock shares. These investors received a total of 1,736 Series E preferred stock (if the Investor elects to convert their Series E preferred stock, each Series E preferred stock shares converts into 4,000 shares of the Company’s common stock shares). During January and April 2020, the Company received equity investments in the amount of $128,000. These investors received a total of 256,000 common stock shares and 256,000 warrants issued to purchase common stock shares at a strike price of $0.25, 256,000 warrants to purchase common stock shares at a strike price of $0.75 and 128 Series D preferred stock (if the Investor elects to convert their Series D preferred stock, each Series D preferred stock shares converts into 3,000 shares of the Company’s common stock shares). Of the amount invested $38,000 was from related parties. Debt Exchanges - 2021 On January 8, 2021, the Company made the final payment of $750,000 out of the total $1,500,000 as required by this exchange agreement with GPB. On June 30, 2021, the Company issued 2,236 series F-2 preferred stock shares in accordance with the terms of the agreement (see NOTE 10: CONVERTIBLE DEBT On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel in exchange for 100 and 85 shares of Series F-2 Preferred Stock, respectively. On March 10, 2021, the Company exchanged $88,000 in accrued consulting fees for Mr. Blumberg for 88 Series F-2 preferred stock shares. On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company exchanged $50,000 of the amount owed of $546,214 for 50 Series F-2 Preferred Shares (convertible into 200,000 common stock shares), a $150,000 unsecured note and Mr. Fowler remains on the Company health insurance plan. The note accrues interest at the rate of 6% (18% in the event of default) beginning on March 22, 2022 and will be payable in monthly installments of $3,600 for four years, with the first payment being due on March 15, 2022. The effective interest rate of the note is 3.0%. Mr. Fowler also has a short-term note for $26,400 and $18,718 in accrued interest. Mr. Fowler forgave $86,554 and may forgive up to $259,661 if the Company complies with the repayment plan described above. Debt Exchanges - 2020 On January 8, 2020, the Company exchanged $2,064,366 in debt for several equity instruments (noted below) that were determined to have a total fair value of $2,065,548, resulting in a loss on extinguishment of debt of $1,183 which is recorded in other income (expense) on the accompanying consolidated statements of operations. The Company also issued 6,957,013 warrants to purchase common stock shares; with exercise prices of $0.25, $0.75 and $0.20. In addition, one of the investors forgave approximately $29,000 of debt, which was recorded as a gain for extinguishment of debt. On June 3, 2020, the Company exchanged $328,422 in debt from Auctus, (summarized in footnote 10: Convertible Notes), On June 30, 2020, the Company exchanged $125,000 in debt (during June 2020, $125,000 in payables had been converted into short-term debt) from Mr. James Clavijo, for 500,000common stock shares and 250,000 warrants to purchase common stock shares. The fair value of the common stock shares was $250,000 (based on a $0.50 fair value for the Company’s stock) and of the warrants to purchase common stock shares was $99,963 (based on a $0.40 black scholes fair valuation). This resulted in a net loss on extinguishment of debt of $224,963 ($349,963 fair value less the $125,000 of exchanged debt). After the exchange transaction a balance was due to Mr. Clavijo of $10,213 which was paid. On July 9, 2020, the Company entered into an exchange agreement with Mr. Bill Wells (one of its former employees) for an outstanding debt to him of $220,000. In lieu of agreeing to dismiss approximately half of what is owed by the Company, Mr. Wells will receive the following: (i) cash payments of $20,000 within 60 days of the signing of the agreement; cash payments over time in the amount of $90,000 in the form of an unsecured note with the Company to be executed within 30 days of a new financing(s) totaling at least $3.0 million. The note shall bear interest of 6.0% and mature over 18 months; (ii) 66,000 common share stock options that vest at a rate of 3,667 per month and have a $0.49 exercise price (if two consecutive payments in (iii) are not made the stock options will be canceled and a cash payment will be required; and (iv) the total amount of forgiveness by creditor of approximately $110,000 shall be prorated according to amount paid. During the year ended December 31, 2020, the Company made a payment of $20,000; this payment allowed the Company to reduce $40,000 in debt, with the corresponding $20,000 difference recorded as a gain. The following table summarizes the 2020 debt exchanges: Total Debt and Accrued Interest Total Debt Total Accrued Interest Common Stock Shares Warrants (Exercise $0.25) Warrants (Exercise $0.75) Warrants (Exercise $0.20) Warrants (Exercise $0.15) Warrants (Exercise $0.50) Aquarius $ 145,544 $ 107,500 $ 38,044 291,088 145,544 145,544 - - - K2 Medical (Shenghuo) 3 803,653 771,927 31,726 1,905,270 704,334 704,334 496,602 - - Mr. Blumberg 305,320 292,290 13,030 1,167,630 119,656 119,656 928,318 - - Mr. Case 179,291 150,000 29,291 896,456 - - 896,456 - - Mr. Grimm 51,110 50,000 1,110 255,548 - - 255,548 - - Mr. Gould 111,227 100,000 11,227 556,136 - - 556,136 - - Mr. Mamula 15,577 15,000 577 77,885 - - 77,885 - - Dr. Imhoff 2 400,417 363,480 36,937 1,699,255 100,944 100,944 1,497,367 - - Ms. Rosenstock 1 50,000 50,000 - 100,000 50,000 50,000 - - - Mr. James 2 2,286 2,000 286 7,745 1,227 1,227 5,291 - - Auctus 328,422 249,119 79,303 500,000 - - - 700,000 - Mr. Clavijo 125,000 125,000 - 500,000 - - - - 500,000 Mr. Wells 4 220,000 220,000 - - - - - - - $ 2,737,847 $ 2,496,316 $ 241,531 7,957,013 1,121,705 1,121,705 4,713,603 700,000 500,000 1 2 3 4 Preferred Stock The Company has authorized 5,000,000 shares of preferred stock with a $.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. Series C Convertible Preferred Stock The board designated 9,000 shares of preferred stock as Series C Convertible Preferred Stock, (the “Series C Preferred Stock”). Pursuant to the Series C certificate of designations, shares of Series C preferred stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for the Company’s common stock. At June 30, 2021 and December 31, 2020, there were 286 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 572,000 common stock shares, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Series C certificate of designations. The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt. Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. In addition, upon conversion of the Series C preferred stock prior to the Dividend End Date, the Company will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. At June 30, 2021 and December 31, 2020, the “make-whole payment” for a converted share of Series C preferred stock would convert to 200 shares of the Company’s common stock. The Series C preferred stock generally has no voting rights except as required by Delaware law. Upon the Company’s liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends. In addition, the purchasers of the Series C preferred stock received, on a pro rata basis, warrants exercisable to purchase an aggregate of approximately 1 share of Company’s common stock. The warrants contain anti-dilution adjustments in the event that the Company issues shares of common stock, or securities exercisable or convertible into shares of common stock, at prices below the exercise price of such warrants. As a result of the anti-dilution protection, the Company is required to account for the warrants as a liability recorded at fair value each reporting period. At June 30, 2021 and December 31, 2020, the exercise price per share was $512,000. Series C1 Convertible Preferred Stock The board designated 20,250 shares of preferred stock as Series C1 Preferred Stock, of which 1,050 shares were issued and outstanding at June 30, 2021 and December 31, 2020. In addition, some holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At June 30, 2021 and December 31, 2020, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock. Between April 27, 2016 and May 3, 2016, the Company entered into various agreements with certain holders of Series C preferred stock, including directors John Imhoff and Mark Faupel, pursuant to which those holders separately agreed to exchange each share of Series C preferred stock held for 2.25 shares of the Company’s newly created Series C1 Preferred Stock and 12 (9,600 pre-split) shares of the Company’s common stock (the “Series C Exchanges”). In connection with the Series C Exchanges, each holder also agreed to roll over the $1,000 stated value per share of the holder’s shares of Series C1 Preferred Stock into the next qualifying financing undertaken by the Company on a dollar-for-dollar basis and, except in the event of an additional $50,000 cash investment in the Company by the holder, to execute a customary “lockup” agreement in connection with the financing. In total, for 1,916 shares of Series C preferred stock surrendered, the Company issued 4,312 shares of Series C1 Preferred Stock and 29 shares of common stock. On August 31, 2018, 3,262.25 shares of Series C1 Preferred Stock were surrendered, and the Company issued 3,262.25 shares of Series C2 Preferred Stock. At June 30, 2021 and December 31, 2020, there were 1,049.25 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C1 preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 2,098,500 common stock shares. The Series C1 preferred stock has terms that are substantially the same as the Series C preferred stock, except that the Series C1 preferred stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C preferred stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt. Series C2 Convertible Preferred Stock On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Preferred Stock, including the chairman of the Company’s board of directors, and the Chief Operating Officer and a director of the Company pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At June 30, 2021 and December 31, 2020, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 6,524,500 common stock shares. The terms of the Series C2 Preferred Stock are substantially the same as the Series C1 Preferred Stock, except that (i) shares of Series C1 Preferred Stock may not be convertible into the Company’s common stock by their holder for a period of 180 days following the date of the filing of the Certificate of Designation (the “Lock-Up Period”); (ii) the Series C2 Preferred Stock has the right to vote as a single class with the Company’s common stock on an as-converted basis, notwithstanding the Lock-Up Period; and (iii) the Series C2 Preferred Stock will automatically convert into that number of securities sold in the next Qualified Financing (as defined in the Exchange Agreement) determined by dividing the stated value ($1,000 per share) of such share of Series C2 Preferred Stock by the purchase price of the securities sold in the Qualified Financing. Series D Convertible Preferred Stock The Board designated 6,000 shares of preferred stock as Series D Preferred Stock, 763 of which remain outstanding. On January 8, 2020, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series D Investors”) pursuant to all obligations under the Series D Certificate of Designation. The Series D Investors included the Chief Executive Officer, Chief Operating Officer and a director of the Company. In total, for $763,000 the Company issued 763 shares of Series D Preferred Stock, 1,526,000 common stock shares, 1,526,000common stock warrants, exercisable at $0.25, and 1,526,000 common stock warrants, exercisable at $0.75. Each Series D Preferred Stock is convertible into 3,000 common stock shares. The Series D Preferred Stock will have cumulative dividends at the rate per share of 10% per annum. The stated value and liquidation preference on the Series D Preferred Stock is $763. The 763 Series D Preferred Shares are convertible into debt at the option of the holder during a prescribed time period. If the Series D Preferred Shares are converted, the Series D preferences are surrendered and the debt is then secured by the Company’s assets. As of June 30, 2021, none of the 763 Series E Preferred Shares have been converted to secured debt. Each share of Series D Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series D Certificate of Designation (the “Series D Conversion Price”). The conversion of Series D Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series D Preferred. If the average of the VWAPs (as defined in the Series D Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series D Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series D Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. On January 8, 2020, the Company also entered into a Registration Rights Agreement (the “Series D Registration Rights Agreement “) with the Series D Investors pursuant to which the Company agreed to file with the SEC, a registration statement on a Form S-3 (or on other appropriate form if a Form S-3 is not available) covering the Common Stock issuable upon conversion of the Series D Warrants within 90 days of the date of the Registration Rights Agreement and cause such registration statement to be declared effective within 120 days of the date of the Registration Rights Agreement. All reasonable expenses related to such registration shall be borne by the Company. During the six months ended June 30, 2021, the Company issued 60,598 common stock shares for the payment of Series D Preferred Stock dividends accrued. As of June 30, 2021, the Company had accrued dividends of $14,306. Series E Convertible Preferred Stock The Board designated 6,000 shares of preferred stock as Series E Preferred Stock, 1,736 of which remain outstanding. During year ended December 31, 2020, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series E Investors”). In total, for $1,736,000 the Company issued 1,736 shares of Series E Preferred Stock. Each Series E Preferred Stock is convertible into 4,000 common stock shares. The Series E Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. The stated value and liquidation preference on the Series E Preferred Stock is $1,736. The Company incurred fees due on these investments of $91,895. Each share of Series E Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series E Certificate of Designation (the “Series E Conversion Price”). The conversion of Series E Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series E Preferred. If the average of the VWAPs (as defined in the Series E Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series E Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series E Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. As of June 30, 2021, the Company had not issued shares as payment of Series E Preferred Stock dividends. As of June 30, 2021, the Company had accrued dividends of $136,667. Series F Convertible Preferred Stock As provided in other disclosures, the Company was oversubscribed for its Series F Convertible Preferred Stock. This required the Company to file an additional Certificate of Designation for Series F-2 Convertible Preferred Stock with substantially the same terms as the Series F Convertible Preferred Stock. The Board designated 1,500 shares of preferred stock as Series F Preferred Stock, 1,421 of which are issued and outstanding. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F Investors”). In total, for $1,421,000 the Company issued 1,421 shares of Series F Preferred Stock. Each Series F Preferred Stock is convertible into 4,000 common stock shares. The Series F Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value and liquidation preference on the Series F Preferred Stock is $1,421. Each share of Series F Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F Certificate of Designation (the “Series F Conversion Price”). The conversion of Series F Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series F Preferred. If the average of the VWAPs (as defined in the Series F Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. As of June 30, 2021, the Company had not issued shares as payment of Series F Preferred Stock dividends. As of June 30, 2021, the Company had accrued dividends of $22,659. Series F-2 Convertible Preferred Stock The Board designated 5,000 shares of preferred stock as Series F-2 Preferred Stock, 3,237 of which are issued and outstanding. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F-2 Investors”). In total, for $678,000 the Company issued 678 shares of Series F-2 Preferred Stock. In addition, the Company exchanged outstanding debt of $2,559,000 for 2,559 shares of Series F-2 Preferred Stock. Each Series F-2 Preferred Stock is convertible into 4,000 common stock shares. The Series F-2 Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value and liquidation preference on the Series F-2 Preferred Stock is $3,339. Below is a summary of the debt exchanges. On January 8, 2021, the Company made the final payment of $750,000 out of the total $1,500,000 as required by this exchange agreement with GPB. On February 24, 2021, the Company agreed to issue 2,236 Series F-2 preferred stock shares in accordance with the terms of the agreement (see NOTE 10: CONVERTIBLE DEBT On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel in exchange for 100 and 85 shares of Series F-2 Preferred Stock, respectively. On March 10, 2021, the Company exchanged $88,000 in accrued consulting fees for Mr. Blumberg 88 shares of Series F-2 preferred stock shares. On March 22, 2021, the Company exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Shares (convertible into 200,000 common stock shares), a $150,000 unsecured note and Mr. Fowler will remain on our health insurance plan. Mr. Fowler forgave $86,554 and may forgive up to $259,661 if the Company complies with the repayment plan. Each share of Series F-2 Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holders of the Series F-2 Preferred. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. As of June 30, 2021, the Company had not issued shares as payment of Series F-2 Preferred Stock dividends. As of June 30, 2021, the Company had accrued dividends of $51,031. Powerup (Series G Convertible Preferred Stock) During January 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $78,500, net to the Company is $75,000, for 91,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. The Company has redeemed all of the Series G preferred stock and the balance is paid. During February 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $53,500, net to the Company is $50,000, for 62,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. Due to the mandatory redemption feature of the Series G preferred stock, the total amount of proceeds of $125,000 was recorded as a liability. On June 4, 2021, the Company redeemed the January 2021 investment of $75,000 for $114,597, this $39,597 difference was recorded as interest expense. As of June 30, 2021, the amount outstanding was $50,000 and is presented as a liability. As of June 30, 2021, the Company has also accrued dividends of $1,915. Warrants The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the six months ended June 30, 2021: Warrants (Underlying Shares) Outstanding, January 1, 2021 28,324,275 Issuances 3,437,300 Canceled / Expired (1,729,662 ) Exercised - Outstanding, June 30, 2021 30,031,913 The Company had the following shares reserved for the warrants as of June 30, 2021: Warrants Exercise Price Expiration Date 7,185,000 (1) $0.20 per share February 12, 2023 325,000 (2) $0.18 per share April 4, 2022 215,000 (3) $0.25 per share July 1, 2022 100,000 (4) $0.25 per share September 1, 2022 7,500,000 (5) $0.20 per share December 17, 2024 250,000 (6) $0.16 per share March 31, 2025 2,597,705 (7) $0.25 per share December 30, 2022 2,597,705 (8) $0.75 per share December 30, 2022 4,713,603 (9) $0.20 per share December 30, 2022 59,600 (10) $0.25 per share April 23, 2023 50,000 (11) $0.25 per share December 30, 2022 50,000 (12) $0.75 per share December 30, 2022 700,000 (13) $0.15 per share May 21, 2023 250,000 (14) $0.50 per share June 23, 2023 1,000 (15) $0.50 per share August 10, 2022 1,250,000 (16) $0.25 per share February 22, 2023 196,000 (17) $0.25 per share March 3, 2024 239,950 (18) $0.25 per share May 5, 2024 207,750 (19) $0.50 per share May 5, 2024 1,130,000 (20) $0.80 per share May 17, 2023 200,000 (21) $0.50 per share May 31, 2023 63,600 (22) $0.80 per share May 31, 2023 150,000 (23) $0.50 per share May 31, 2024 30,031,913 (1) Exchanged in January 2020 from amount issued as part of a February 2016 private placement with senior secured debt holder (2) Issued to investors for a loan in April 2019 (3) Issued to investors for a loan in July 2019 (4) Issued to investors for a loan in September 2019 (5) Issued to investors for a loan in December 2019 (6) Issued to investors for a loan in January 2020 (7) Issued to investors as part of Series D Preferred Stock Capital raise in December 2020 (8) Issued to investors as part of Series D Preferred Stock Capital raise in December 2020 (9) Issued to investors as part of Series D Preferred Stock Capital raise in December 2020 (10) Issued to a consultant for services in April 2020 (11) (12) (13) (14) (

STOCK OPTIONS

STOCK OPTIONS	6 Months Ended
	Jun. 30, 2021
STOCK OPTIONS
5. STOCK OPTIONS	5. STOCK OPTIONS On July 14, 2020, the Company granted 1,800,000 stock options to employees and consultants. The new Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The plan provides for stock options to be granted up to 10% of the outstanding common stock shares. Outstanding stock options as of June 30, 2021 are as follows: Stock options vested 892,977 Stock options unvested 932,023 Total stock options granted at June 30, 2021 1,825,000 Stock option activity for the six months ended June 30, 2021 is as follows: Shares Weighted Average Exercise Price Outstanding at beginning of year 1,800,000 $ 0.49 Options granted 25,000 0.49 Options exercised - - Options expired/forfeited - - Outstanding at end of the period 1,825,000 $ 0.49

LITIGATION AND CLAIMS

LITIGATION AND CLAIMS	6 Months Ended
	Jun. 30, 2021
COMMITMENTS & CONTINGENCIES (Note 7)
6. LITIGATION AND CLAIMS	6. LITIGATION AND CLAIMS From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in the aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular year. As of June 30, 2021, and December 31, 2020, there was no accrual recorded for any potential losses related to pending litigation.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
COMMITMENTS & CONTINGENCIES (Note 7)
7. COMMITMENTS AND CONTINGENCIES	7. COMMITMENTS AND CONTINGENCIES Operating Leases In December 2009, the Company moved its offices, which comprise its administrative, research and development, marketing and production facilities to 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092. The Company leases 12,835 square feet. On October 27, 2020, the Company amended the lease of its offices in Norcross, Georgia. The Company has extended the lease for sixty-two (62) months. The lease will begin on April 1, 2021 and end on May 31, 2026. Monthly rents for the one-year periods beginning on April 1, 2021 and ending on May 31, 2026 are: $8,824, $9,091, $9,370, $9,648, $9,936, and $10,236. Also, the Company will pay any additional rent for the Company’s proportionate share of basic costs and all other charges when due and payable under the lease. These costs are accounted for as variable costs and are not determinable at the lease commencement date and are not included in the measurement of the lease asset and liabilities. The landlord will abate the rent for the first two months. In addition, the Company will have a five-year renewal option effective June 1, 2026. The rent for the renewal option will be based upon prevailing market rate and shall escalate by three percent (3%). As of June 30, 2021, the right of use asset calculated for the amended lease was $403,014. The Company recognizes lease expense on a straight-line basis over the estimated lease term and combine lease and non-lease components. Future minimum rental payments at June 30, 2021 under non-cancellable operating leases for office space and equipment are as follows (in thousands): Year Amount 2021 $ 62 2022 108 2023 112 2024 115 2025 118 Thereafter 50 Total 565 Less: Interest 146 Present value of lease liability $ 419 Related Party Contracts On June 5, 2016, the Company entered into a license agreement with Shenghuo Medical, LLC pursuant to which the Company granted Shenghuo an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Shenghuo was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license extended to manufacturing in those countries as well. Under the terms of the license agreement, once Shenghuo was capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, Shenghuo would pay the Company a royalty equal to $2.00 or 20% of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within Shenghuo’s exclusive territories. In connection with the license grant, Shenghuo was to underwrite the cost of securing approval of LuViva with Chinese Food and Drug Administration. At its option, Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s board of directors (current director Richard Blumberg is the designee). On September 6, 2016, the Company entered into a royalty agreement with one of its directors, John Imhoff, and another stockholder, Dolores Maloof, pursuant to which the Company sold to them a royalty of future sales of single-use cervical guides for LuViva. Under the terms of the royalty agreement, and for consideration of $50,000, the Company will pay them an aggregate perpetual royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable that the Company sells (or that is sold by a third party pursuant to a licensing arrangement with the Company). On January 22, 2020, the Company entered into a promotional agreement with a related party, which is partially owned by Mr. Blumberg, to provide investor and public relations services for a period of two years. As compensation for these services, the Company will issue a total of 5,000,000 warrants, broken into four tranches of 1,250,000. The warrants have a strike price of $0.25 and are subject to vesting based upon the close of the Series D offering and a minimum share price based on the 30-day VWAP. If the minimum share price per the terms of the agreement is not achieved, the warrants will expire three years after the issuance date. The warrants were valued using the Black Scholes model on the grant date of January 22, 2020, which resulted in a total fair value of $715,000. The Company did not appropriately expense the services received in connection with this agreement in 2020. The Company booked consulting expenses of $397,222 for the quarter ended June 30, 2021, which includes twelve months of expense for the year ended December 31, 2020. If the Company had properly accounted for the straight-line expensing of these services in 2020, net loss would have increased by $318,000 for a total net loss of $719,000 for the year ended December 31, 2020 and accumulated deficit would have increased to $140.2 million as of December 31, 2020. Unrecognized consulting expense to be recognized under this agreement is $238,534 as of June 30, 2021. On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg. As a result of the consulting agreement Mr. Blumberg provided $350,000, which was recorded to subscription receivable, to the Company in exchange for the following: (1) on September 26, 2021, 900,000 3-year warrants with an exercise price of $0.30 and 400,000 common stock shares; (2) on March 26, 2022, 900,000 3-year warrants with an exercise price of $0.40 and 400,000 common stock shares; (3) on September 26, 2022, 900,000 3-year warrants with an exercise price of $0.50 and 400,000 common stock shares; and (4) on March 26, 2023, 900,000 3-year warrants with an exercise price of $0.60 and 400,000 common stock shares. Other Commitments On July 24, 2019, Shandong Yaohua Medical Instrument Corporation (“SMI”), agreed to modify its existing agreement. Under the terms of this modification, the Company agreed to grant (1) exclusive manufacturing rights, excepting the disposable cervical guides for the Republic of Turkey, and the final assembly rights for Hungary, and (2) exclusive distribution and sales for LuViva in jurisdictions, subject to the following terms and conditions. First, SMI shall complete the payment for parts, per the purchase order, for five additional LuViva devices. Second, in consideration for the $885,144 that the Company received, SMI will receive 12,147 common stock shares. Third, SMI shall honor all existing purchase orders it has executed to date with the Company, in order to maintain jurisdiction sales and distribution rights. If SMI needs to purchase cervical guides then it will do so at a cost including labor, plus ten percent markup. The Company will provide 200 cervical guides at no cost for the clinical trials. Fourth, the Company and SMI will make best efforts to sell devices after CFDA approval. With an initial estimate of year one sales of 200 LuViva devices; year two sales of 500 LuViva devices; year three sales of 1,000 LuViva devices; and year four sales of 1,250 LuViva devices. Fifth, SMI shall pay for entire costs of securing approval of LuViva with the Chinese FDA. Sixth, SMI shall arrange, at its sole cost, for a manufacturer in China to build tooling to support manufacture. In addition, SMI retains the right to manufacture for China, Hong Kong, Macau and Taiwan, where SMI has distribution and sales rights. For each single-use cervical guide sold by SMI in the jurisdictions, SMI shall transfer funds to escrow agent at a rate of $1.90 per device chip. If within 18 months of the license’s effective date, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Commercialization is defined as: filing an application with the Chinese FDA for the approval of LuViva; any assembly or manufacture of the devices or disposables that begins in China; and purchase of at least 10 devices and disposables for clinical evaluations and regulatory use and or sales in the jurisdictions. On March 5, 2020 the Company had recorded an accrued liability for SMI of $692,335, which was reclassified to additional paid in capital and 12,147 common stock shares. Contingencies Based on the current outbreak of the Coronavirus SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets, there could be additional repercussions to the Company’s operating business, including but not limited to, the sourcing of materials for product candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations, which may include the availability or the continued availability of patients for trials due to such things as quarantines, conduct of patient monitoring and clinical trial data retrieval at investigational study sites. The future impact of the outbreak is highly uncertain and cannot be predicted, and the Company cannot provide any assurance that the outbreak will not have a material adverse impact on the Company’s operations or future results or filings with regulatory health authorities. The extent of the impact to the Company, if any, will depend on future developments, including actions taken to contain the coronavirus.

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Jun. 30, 2021
NOTES PAYABLE
8. NOTES PAYABLE	8. NOTES PAYABLE Notes Payable in Default At June 30, 2021 and December 31, 2020, the Company maintained notes payable to both related and non-related parties totaling approximately $308,000 and $329,000, respectively. These notes are short term, straight-line amortizing notes. The notes carry annual interest rates between 0% and 10% and have default rates as high as 20%. The Company is accruing interest at the default rate of 18.0% on loan to Mr. Mermelstein. As described in Note 4: STOCKHOLDERS’ DEFICIT, During 2021, notes payable of $1,000 due to Dr. Cartwright were paid off and notes payable of $26,000 due to Mr. Fowler were brought current and not in default. The note payable to GPB was exchanged as part of the exchange as described in Note 10: The following table summarizes the Notes payable in default, including related parties June 30, 2021 December 31, 2020 Mr. Mermelstein $ 308 $ 285 Dr. Cartwright - 1 Mr. Fowler - 26 GPB - 17 Notes payable in default $ 308 $ 329 The notes payable to related parties was nil of the $308,000 balance at June 30, 2021 and $27,000 of the $329,000 balance at December 31, 2020. Short Term Notes Payable At June 30, 2021 and December 31, 2020, the Company maintained short term notes payable to both related and non-related parties totaling $65,000 and $96,000, respectively. These notes are short term, straight-line amortizing notes. The notes carry annual interest rates between 5% and 19%. During 2019, the Company issued promissory notes to Mr. Cartwright and Mr. Faupel, in the amounts of approximately $41,000 and $5,000, respectively. The notes were initially issued with 0% interest, however interest increased to 6.0% interest 90 days after the Company received $1,000,000 in financing proceeds. On July 4, 2020, the Company entered into a premium finance agreement to finance its insurance policies totaling $109,000. The note requires monthly payments of $11,299, including interest at 4.968% and matured in April 2021. As of June 30, 2021, the balance was paid. On December 21, 2016 and January 19, 2017, the Company issued promissory notes to Mr. Fowler, in the amounts of approximately $26,400 and accrued interest of $18,718. This note carries a monthly payment of $3,850. The notes were initially issued with 0% interest and then went into default with an interest rate of 18%. As part of the March 22, 2021, exchange agreement these notes were brought current and will accrue interest at 6%. As of June 30, 2021 the outstanding balance was $19,508 (At December 31, 2020 this note was recorded in the Notes payable in default section of the Balance Sheet). The following table summarizes the Short-term notes payable, including related parties June 30, 2021 December 31, 2020 Dr. Cartwright $ 41 $ 46 Dr. Faupel 5 5 Mr. Fowler 19 - Premium Finance (insurance) - 45 Short-term notes payable, including related parties $ 65 $ 96 The short-term notes payable past due to related parties was $65,000 at June 30, 2021 and $51,000 of the $96,000 balance at December 31, 2020. Troubled Debt Restructuring During the six months ended June 30, 2020, the debt extinguished for Notes Payable was $1,808,712 this debt was exchanged for common stock shares and warrants as described in the Notes to the financial statements. The Company determined that these notes had a total fair value of $2,235,811, resulting in a loss on extinguishment of debt of $427,099 which is recorded in other income (expense) on the accompanying consolidated statements of operations. Included in that total was an amount that an investor forgave of approximately $29,000 of debt, which was recorded as a gain for extinguishment of debt. This debt extinguished met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being in default on several of its loans the debt is considered troubled debt.

SHORT-TERM CONVERTIBLE DEBT

SHORT-TERM CONVERTIBLE DEBT	6 Months Ended
	Jun. 30, 2021
SHORT-TERM CONVERTIBLE DEBT
9. SHORT-TERM CONVERTIBLE DEBT	9. SHORT-TERM CONVERTIBLE DEBT Related Party Convertible Note Payable – Short-Term On June 5, 2016, the Company entered into a license agreement with a distributor pursuant to which the Company granted the distributor an exclusive license to manufacture, sell and distribute the Company’s LuViva Advanced Cervical Cancer device and related disposables in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. The distributor was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license will extend to manufacturing in those countries as well. As partial consideration for, and as a condition to, the license, and to further align the strategic interests of the parties, the Company agreed to issue a convertible note to the distributor, in exchange for an aggregate cash investment of $200,000. The note will provide for a payment to the distributor of $240,000, due upon consummation of any capital raising transaction by the Company within 90 days and with net cash proceeds of at least $1.0 million. As of December 31, 2019, the Company had a note due of $512,719. As of December 31, 2020, the note had been exchanged for common stock shares and warrants. This was part of the exchange made on January 8, 2020, for $790,544 of debt outstanding for: 1,905,270 common stock shares issued on March 23, 2020; 496,602 warrants issued to purchase common stock shares at a strike price of $0.20; 692,446 warrants issued to purchase common stock shares at a strike price of $0.25; and 692,446 warrants issued to purchase common stock shares at a strike price of $0.75. Short-term Convertible Notes Payable Auctus On December 17, 2019, the Company entered into a securities purchase agreement and convertible note with Auctus. The convertible note issued to Auctus will be for a total of $2.4 million. The first tranche of $700,000 was received in December 2019 and matures December 17, 2021 and accrues interest at a rate of ten percent (10%) . The note may not be prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices shall equal the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price shall mean 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event shall the variable conversion price be less than $0.15. If an event of default under this note occurs and/or the note is not extinguished in its entirety prior to December 17, 2020 the $0.15 price shall no longer apply. In connection with the first tranche of $700,000, the Company issued to 7,500,000 warrants to purchase common stock at an exercise price of $0.20. The fair value of the warrants at the date of issuance was $745,972 and was $635,000 allocated to the warrant liability and a loss of $110,972 was recorded at the date of issuance for the amount of the fair value in excess of the net proceeds received of $635,000. The $700,000 proceeds were received net of debt issuance costs of $65,000 (net proceeds of $635,000, after administrative and legal expenses Company received $570,000). The Company used $65,000 of the proceeds to make a partial payment of the $89,250 convertible promissory note issued on July 3, 2018 to Auctus. The Company made a $700,000 payment on June 1, 2021, which resulted in a prepayment penalty of $350,000 being assessed to the Company. The Company recorded this prepayment penalty as interest expense. Interest will not be assessed on the prepayment penalty. As of June 30, 2021 and December 31, 2020, $350,000 and $700,000, respectively, remained outstanding. As of June 30, 2021, accrued interest was paid in full and at December 31, 2020 $73,889 remained outstanding. Further, as June 30, 2021 and December 31, 2020, the Company had unamortized debt issuance costs of $0 and $31,146, respectively and an unamortized debt discount on warrants of $0, and $304,271, respectively and providing a net balance of $350,000 and $364,583, respectively. On May 27, 2020, the Company received the second tranche in the amount of $400,000, from the December 17, 2019 securities purchase agreement and convertible note with Auctus. The net amount paid to the Company was $313,000 This second tranche is part of the convertible note issued to Auctus for a total of $2.4 million of which $700,000 has already been provided by Auctus. The notes maturity date is December 17, 2021 and an interest rate of ten percent (10%) . The note may not be prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices shall equal the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price shall mean 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event shall the variable conversion price be less than $0.15. If an event of default under this note occurs and/or the note is not extinguished in its entirety prior to December 17, 2020 the $0.15 price shall no longer apply. The last tranche of $1.3 million will be received within 60 days of the S-1 registration statement becoming effective. The conversion price of the notes will be at market value with a minimum conversion amount of $0.15. In addition, as part of this transaction the Company was required to pay a 2.0% fee to a registered broker-dealer. As of June 30, 2021 and December 31, 2020, $400,000 remained outstanding and accrued interest of $44,333 and $24,222, respectively. Further, as of June 30, 2021 and December 31, 2020, the Company had unamortized debt issuance costs of $30,336 and $47,086, providing a net balance of $369,664 and $352,914. As of June 30, 2021 the bifurcated/derivative liability was $28,800. The total outstanding balance for the first two tranches outstanding as of June 30, 2021 and December 31, 2020, was approximately $400,000 and $1,100,000, respectively. In addition, the Company determined that the conversion option needed to be bifurcated from the debt arrangement and will be valued at fair value each reporting period. The initial value at the date of issuance deemed to be $0 due to the presence of the $0.15 floor price. The following table summarizes the Short-term Convertible Notes Payable (including debt in default): June 30, 2021 December 31, 2020 Auctus Tranche 2 (December 17, 2019 note) $ 400 $ 400 Auctus prepayment penalty (December 17, 2019 note) 350 - Auctus Tranche 1 (December 17, 2019 note) - 700 Auctus (March 31, 2020 note) - 113 Debt discount and issuance costs to be amortized (30 ) (262 ) Convertible notes payable – short-term $ 720 $ 951 Troubled Debt Restructuring The prepayment penalty to Auctus was recorded as debt extinguished for Short-term Convertible Notes Payable. This prepayment penalty resulted in a loss of $350,000. This debt extinguished met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being in default on several of its loans the debt is considered troubled debt. During 2021, the prepayment penalty to Auctus was recorded as debt extinguished for Short-term Convertible Notes Payable. This prepayment penalty resulted in a loss of $350,000. In addition, the gain recognized for the extinguishment of the derivative liability due to the payoff of the $700,000 loan to Auctus of $84,000 was recorded. This debt extinguished met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being in default on several of its loans the debt is considered troubled debt.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	6 Months Ended
	Jun. 30, 2021
SHORT-TERM CONVERTIBLE DEBT
10. CONVERTIBLE DEBT	10. CONVERTIBLE DEBT Short-term convertible notes payable Senior Secured Promissory Note As of June 30, 2021, all Senior Secured debt due to GPB had been exchanged for 2,236 Series F-2 preferred stock shares in accordance with the terms of the January 15, 2020 exchange agreement. In addition, the common stock purchase warrant exercise price had been adjusted to $0.20 and the number of common stock shares exchangeable for was 7,185,000. The exchange agreement was subject to the Company meeting repayment conditions, which the Company did. Those conditions involved in part the repayment of $450,000, $100,000 and $950,000 for the completion of each Auctus financing tranche. Further on September 2, 2020, the Company made a payment of $50,000, which provided the Company a four-month forbearance as well as paying and additional $150,000 to reduce the balance outstanding at that time. On January 8, 2021, the Company made the final payment of $750,000 as required by this exchange agreement with GPB. On February 12, 2016, the Company entered into a securities purchase agreement with GPB Debt Holdings II LLC (“GPB”) for the issuance of a $1,437,500 senior secured convertible note for an aggregate purchase price of $1,029,000 (representing an original issue discount of $287,500 and debt issuance costs of $121,000). On May 28, 2016, the balance of the note was increased by $87,500 for a total principal balance of $1,525,000. On December 7, 2016, the Company entered into an exchange agreement with GPB and as a result the principal balance increased by a transfer $312,500 (see – “Senior Secured Promissory Note”) for a total principal balance of $1,837,500. In connection with the transaction, on February 12, 2016, the Company and GPB entered into a four-year consulting agreement, pursuant to which the investor will provide management consulting services to the Company in exchange for a royalty payment, payable quarterly, equal to 3.85% of the Company’s revenues from the sale of products. As of June 30, 2021 and December 31, 2020, and 2019, GPB had earned approximately $35,000 in royalties that are unpaid. Based on the exchange agreement GPB will no longer earn royalties. As of December 31, 2020, the balance due on the convertible debt was $1,709,414, consisting of principal of $1,362,384 and a prepayment penalty of $347,030. Interest accrued on the note total $1,233,637 at December 31, 2020, and is included in accrued expenses on the accompanying consolidated balance sheet. The Company used a placement agent in connection with the transaction. For its services, the placement agent received a cash placement fee equal to 4% of the aggregate gross proceeds from the transaction and a warrant to purchase shares of common stock equal to an aggregate of 6% of the total number of shares underlying the securities sold in the transaction, at an exercise price equal to, and terms otherwise identical to, the warrant issued to the investor. Finally, the Company agreed to reimburse the placement agent for its reasonable out-of-pocket expenses. The warrants issued to that placement agent had expired during the six months ended June 30, 2021. Other Convertible Debt GHS Effective May 19, 2017, the Company entered into a securities purchase agreement with GHS for the purchase of a $66,000 convertible promissory note for the purchase of $60,000 in net proceeds (representing a 10% original issue discount of $6,000). The accrued interest rate of 8% per year until it matured in December 31, 2017. Beginning February 2018, the note is convertible, in whole or in part, at the holder’s option, into shares of the Company’s stock at a conversion price equal to 60% of the lowest trading price during the 25 trading days prior to conversion. Upon the occurrence of an event of default, the note will bear interest at a rate of 20% per year and the holder of the note may require the Company to redeem or convert the note at 150% of the outstanding principal balance. GHS converted $12,700 of principal and accrued interest during the year ended December 31, 2019. On December 16, 2020, the Company paid $25,000 on the note balance. At June 30, 2021 the note was paid in full. On December 31, 2020, the balance due on this note was $63,520 including a default penalty of $37,926. Interest accrued on the note totaled $17,816, at December 31, 2020 and is included in accrued expenses on the accompanying consolidated balance sheet. Effective May 17, 2018, the Company entered into a securities purchase agreement with GHS for the purchase of a convertible promissory note with a principal of $9,250 for a purchase price of $7,500 (representing an original issue discount of $750 and debt issuance costs of $1,000). The note accrued interest at a rate of 8% per year until its matured June 17, 2019. Beginning February 2018, the note is convertible, in whole or in part, at the holder’s option, into shares of the Company’s stock at a conversion price equal to 70% of the lowest trading price during the 25 trading days prior to conversion (if the note cannot be converted due to Depository Trust Company freeze then rate decreases to 60%). Upon the occurrence of an event of default, the note will bear interest at a rate of 20% per year and the holder of the note may require the Company to redeem or convert the note at 150% of the outstanding principal balance. As of June 30, 2021, the note was paid in full. At December 31, 2020, the balance due on this note was $14,187, including a default penalty of $4,937. Interest accrued on the note totaled $5,006 at December 31, 2020, and is included in accrued expenses on the accompanying consolidated balance sheet. Effective June 22, 2018, the Company entered into a securities purchase agreement with GHS for the purchase of a $68,000 convertible promissory note for a purchase price of $60,000 (representing an original issue discount of $6,000 and debt issuance costs of $2,000). At issuance, the Company recorded a $29,143 beneficial conversion feature, which was fully amortized at December 31, 2019. The accrued interest at a rate of 10% per year until it matured on June 22, 2019. Beginning May 2019, the note is convertible, in whole or in part, at the holder’s option, into shares of the Company’s stock at a conversion price equal to 70% of the lowest trading price during the 25 trading days prior to conversion (if the note cannot be converted due to Depository Trust Company freeze then rate decreases to 60%). Upon the occurrence of an event of default, the note will bear interest at a rate of 20% per year and the holder of the note may require the Company to redeem or convert the note at 150% of the outstanding principal balance. At June 30, 2021 the note was paid in full. At December 31, 2020, the balance due on this note was $103,285 and includes a default penalty of $35,285. Interest accrued on the note totals $0 and $39,644 at June 30, 2021 and December 31, 2020, respectively, and is included in accrued expenses on the accompanying consolidated balance sheet. Auctus On May 22, 2020, the Company entered into an exchange agreement with Auctus. Based on this agreement the Company exchanged three outstanding notes, in the amounts of $150,000, $89,250, and $65,000 for a total amount $328,422 of debt outstanding, as well as any accrued interest and default penalty, for: $160,000 in cash payments (payable in monthly payments of $20,000), converted a portion of the notes pursuant to original terms of the notes into 500,000 restricted common stock shares (shares were issued on June 3, 2020); and 700,000 warrants issued to purchase common stock shares at a strike price of $0.15. The fair value of the common stock shares was $250,000 (based on a $0.50 fair value for the Company’s stock) and of the warrants to purchase common stock shares was $196,818 (based on a $0.281 black scholes fair valuation). During the year ended December 31, 2020, the Company paid $100,000 to reduce the outstanding balance. As of June 30, 2021, the balance was paid in full. At December 31, 2020, a balance of $40,000 remained to be paid for these exchanged loans. Auctus notes exchanged in the May 22, 2020 transaction Effective March 20, 2018, the Company entered into a securities purchase with Auctus Fund, LLC (“Auctus”) for the issuance of a $150,000 convertible promissory note and warrants exercisable for 4,262 shares of the Company’s common stock. At issuance, the Company recorded a $97,685 beneficial conversion feature, which was fully amortized at December 31, 2018. The warrants are exercisable at any time, at an exercise price equal to $0.04 per share, subject to certain customary adjustments and price-protection provisions contained in the warrant. The warrants have a five-year term. The note accrued interest at a rate of 12% per year until it matured in December 2018. Beginning December 2018, the note is convertible, in whole or in part, at the holder’s option, into shares of the Company’s stock at a conversion price equal to 60% of the lowest trading price during the 20 trading days prior to conversion. Upon the occurrence of an event of default, the note will bear interest at a rate of 24% per year and the holder of the note may require the Company to redeem or convert the note at 150% of the outstanding principal balance. On May 22, 2020, the default penalty and outstanding interest was exchanged as described in the preceding paragraph. As of June 30, 2021, the note was paid in full. During the year ended December 31, 2020, the Company paid $100,000 to reduce the outstanding balance. As of December 31, 2020, a balance of $40,000 remained to be paid for these exchanged loans. Convertible Notes in default On March 31, 2020, we entered into a securities purchase agreement with Auctus Fund, LLC for the issuance and sale to Auctus of $112,750 in aggregate principal amount of a 12% convertible promissory note. On June 30, 2020, we issued the note to Auctus and issued 250,000 five-year common stock warrants at an exercise price of $0.16. On April 3, 2020, we received net proceeds of $100,000. The note matured on January 26, 2021 and accrues interest at a rate of 12% per year. We may not prepay the note, in whole or in part. After the 90 th The following table summarizes the Convertible notes (including debt in default) June 30, 2021 December 31, 2020 GPB $ - $ - $ 1,709 $ 1,709 GHS - 64 - 14 - - 103 181 Auctus 169 169 - 40 Convertible notes, past due (including debt in default) $ 169 $ 1,930 As of June 30, 2021, the outstanding balances were $168,561 for debt in default for Auctus. At December 31, 2021 the balance of $1,930,000 was past due. Troubled Debt Restructuring During 2021, the Company restructured debt with GPB resulting in the exchange of $1,709,000 of convertible debt. This debt restructure met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor.

LONG TERM DEBT

LONG TERM DEBT	6 Months Ended
	Jun. 30, 2021
LONG TERM DEBT
11. LONG-TERM DEBT	11. LONG-TERM DEBT Long-term Debt – Related Parties On July 24, 2019, Dr. Faupel and Mr. Cartwright agreed to an addendum to the debt restructuring exchange agreement and to modify the terms of the original exchange agreement. Under this modification Dr. Faupel and Mr. Cartwright agreed to extend the note to be due in full on the third anniversary of that agreement. The modification also included simple interest at a 6% rate, with the principal and accrued interest due in total at the date of maturity or February 18, 2023. During the quarter ended September 30, 2018, the Company entered into an exchange agreement dated July 14, 2018, Dr Faupel, agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $661,000 for a $207,000 promissory note dated September 4, 2018. As a result of the exchange agreement, the Company recorded a gain for extinguishment of debt of $199,000 and a capital contribution of $235,000 during the year ended December 31, 2018. The resulting difference of $20,000 was recorded to accrued interest. In the July 20, 2018 exchange agreement, Dr, Cartwright, agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,000 for a $319,000 promissory note dated September 4, 2018. As a result of the exchange agreement, the Company recorded a gain for extinguishment of debt of $840,000 and a capital contribution of $432,000 during the year ended December 31, 2018. The resulting difference of $30,000 was recorded to accrued interest and elimination of debt. On February 19, 2021, the Company entered into a new promissory note replacing the original note from September 4, 2018, with Mark Faupel and Gene Cartwright. For Dr. Cartwright the principal amount on the new note was $267,085, matures on February 18, 2023, and will accrue interest at a rate of 6%. For Dr. Faupel the principal amount on the new note was $153,178, matures on February 18, 2023, and will accrue interest at a rate of 6%. On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel in exchange for 100 and 85 shares of Series F-2 Preferred Stock, respectively. The table below summarizes the detail of the exchange agreement: For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange $ 661 Amount forgiven (454 ) Total Interest accrued through December 31, 2020 29 Balance outstanding at December 31, 2020 $ 236 Exchange for Series F-2 Preferred Stock (85 ) Interest accrued through June 30, 2021 7 Balance outstanding at June 30, 2021 $ 158 For Dr. Cartwright: Salary $ 337 Bonus 675 Interest on compensation 528 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange $ 1,621 Amount forgiven (1,302 ) Total Interest accrued through December 31, 2020 45 Balance outstanding at December 31, 2020 $ 364 Exchange for Series F-2 Preferred Stock (100 ) Interest accrued through June 30, 2021 7 Balance outstanding at June 30, 2021 $ 271 On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company exchanged $50,000 of the amount owed of $546,214 for 50 share of Series F-2 Preferred Shares (convertible into 200,000 common stock shares), and a $150,000 unsecured note and Mr. Fowler remains on the Company’s health insurance plan. The note accrues interest at the rate of 6% (18% in the event of default) beginning on March 22, 2022 and is payable in monthly installments of $3,580 for four years, with the first payment being due on March 15, 2022. The effective interest rate of the note is 3.0%. Mr. Fowler also has a short-term note for $26,400 and $18,718 in accrued interest. Mr. Fowler forgave $86,554 and may forgive up to $259,661 if the Company complies with the repayment plan described above. Future debt obligations which are recorded in the Long-term debt-related parties includes: $271,000, $158,000 and $150,000 for a total of $579,000 for Dr. Cartwright, Dr. Faupel, and Mr. Fowler, respectively. Future debt obligations at June 30, 2021 for Long-term Debt – Related Parties are as follows (in thousands): Year Amount 2021 $ - 2022 - 2023 462 2024 43 2025 43 Thereafter 31 Totals $ 579 Long-term debt On May 4, 2020, the Company received a loan from the Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) as part of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in the amount of $50,184. The loan bears interest at a rate of 1.00%, and matures in 24 months, with the principal and interest payments being deferred until the date of forgiveness with interest accruing, then converting to monthly principal and interest payments, at the interest rate provided herein, for the remaining eighteen (18) months. Lender will apply each payment first to pay interest accrued to the day Lender received the payment, then to bring principal current, and will apply any remaining balance to reduce principal. Payments must be made on the same day as the date of this Note in the months they are due. Lender shall adjust payments at least annually as needed to amortize principal over the remaining term of the Note. Under the provisions of the PPP, the loan amounts will be forgiven as long as: the loan proceeds are used to cover payroll costs, and most mortgage interest, rent, and utility costs over a 24-week period after the loan is made; and employee and compensation levels are maintained. In addition, payroll costs are capped at $100,000 on an annualized basis for each employee. Not more than 40% of the forgiven amount may be for non-payroll costs. As of June 30, 2021 and December 31, 2020, the outstanding balance was $24,331 (this amount is recorded in current portion of long-term debt) and $50,477, including $331 and $293 in accrued interest, respectively. The Company was notified that the application for loan forgiveness was approved in the amount of $23,742 in principal and $234 in interest. The Company is planning on appealing the amount forgiven. Long-term convertible debt 10% Senior Unsecured Convertible Debenture On May 17, 2021, the Company issued 10% Senior Unsecured convertible debentures to investors, which mature on May 17, 2024 (the “Maturity Date”). The Company subscribed $1,130,000 of the $1,000 convertible debentures. The terms of the debentures are as follows: 1) the principal amount of some or all of the convertible debentures and accrued interest are convertible into common stock shares at the holder’s option, at a price of $0.50 per common stock share (the “conversion price”), subject to adjustment in certain events, at any time prior to maturity date; 2) upon successful uplist to a U.S. National Exchange, the note will automatically convert into the uplisting financing; 3) each debenture unit will have a right to 1,000 warrants for common stock shares, warrants have an exercise price of $0.80 and an expiration date of May 17, 2023; 4) if a Change of Control (as defined in the Convertible Debenture Certificate) occurs prior to the Maturity Date, unless the holder elects in writing to convert the Convertible Debentures into common shares, the Company will repay in cash upon the closing of such Change of Control all outstanding principal and accrued interest under each Convertible Debenture plus a Change of Control premium equal to an additional 3% of the outstanding principal sum under such Convertible Debenture. Prior to the closing of an Change of Control, in lieu of repayment as set forth in the preceding sentence, the holder has the right to elect in writing to convert, effective immediately prior to the effective date of such Change of Control, all outstanding principal and accrued Interest under the Convertible Debentures into common shares at the Conversion Price; 5) Subject to a holder’s option of electing conversion prior to the Redemption Date (as such term is defined below), on or after the date that is 24 months from the Closing Date if the daily volume weighted average trading price of the common shares is $1.50 per common share or more for each trading day over a 30 consecutive trading day period, the Company may, at any time and from time to time thereafter (the “Redemption Date”), at its option, redeem all, or any portion of the Convertible Debentures for either: (i) a cash payment (in the form of a certified cheque or bank draft) that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date; or (ii) by issuing and delivering common shares to the holders of Convertible Debentures at a deemed price of US$0.50 per common share that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date, or any combination of (i) or (ii), upon not less than 30 days and not more than 60 days prior written notice in the manner provided in the Debenture Certificate, to the holder of Convertible Debentures. At June 30, 2021, the balance due on the 10% Senior Secured Convertible Debenture was $1,130,000 and accrued interest of $14,103. At June 30, 2021, the Company had also recorded a bond payable discount of $375,000, leaving a net balance of $755,000. At June 30, 2021, the Company had unamortized debt issuance costs of $83,520, for a net balance of $341,597. Troubled Debt Restructuring The debt extinguished for Dr. Cartwright, Mr. Fowler and Dr. Faupel meet the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being in default on several of its loans the debt is considered troubled debt. During the six months ended June 30, 2021, the Company recorded a gain of $86,554 for Mr. Fowler’s debt exchange.

INCOME (LOSS) PER COMMON SHARE

INCOME (LOSS) PER COMMON SHARE	6 Months Ended
	Jun. 30, 2021
INCOME (LOSS) PER COMMON SHARE
12. INCOME (LOSS) PER COMMON SHARE	12. INCOME (LOSS) PER COMMON SHARE Basic net income (loss) per share attributable to common stockholders, amounts are computed by dividing the net income (loss) plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the year. Diluted net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends, deemed dividends on preferred stock, after-tax interest on convertible debt and convertible dividends by the weighted average number of shares outstanding during the year, plus Series C, Series D, Series E, Series F and Series F-2 convertible preferred stock, Series G preferred stock, convertible debt, convertible preferred dividends and warrants convertible into common stock shares. The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. In thousands June 30, 2021 2020 Net loss $ (1,871 ) $ (4,049 ) Basic weighted average number of shares outstanding 13,226 8,463 Net loss per share (basic) $ (0.14 ) $ (0.48 ) Diluted weighted average number of shares outstanding 13,226 8,463 Net loss per share (diluted) $ (0.14 ) $ (0.48 ) Dilutive equity instruments (number of equivalent units): Stock options - - Preferred stock 18,316 - Convertible debt 1,281 31,228 Warrants 17,869 5,341 Total Dilutive instruments 37,466 36,569 For period of net loss, basic and diluted earnings per share are the same as the assumed exercise of warrants and the conversion of convertible debt are anti-dilutive. Troubled Debt Restructuring As provided in the preceding footnotes, several transactions met the basic criteria for troubled debt, which are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being in default on several of its loans the debt is considered troubled debt. As of June 30, 2021, the total troubled debt restructuring was $179,000, since this amount has already been recorded as a loss on extinguishment of debt the loss would not have any impact on the per share calculation. As of June 30, 2020, the troubled debt restructuring for Convertible Debt, based on the reduction in warrants outstanding would have an effect on the Company’s diluted earnings per share calculation for June 30, 2020, but not on the basic earnings per share calculation. However, for the six months ended June 30, 2020 the basic and diluted earnings per share would have remained the same as the Company had a loss.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2021
SUBSEQUENT EVENTS
13. SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS On July 22, 2021 the Company held its 2021 Annual Meeting of Stockholders. At this meeting the following proposals were approved: (1) the election of the director-nominees (the “Directors”) of the Company’s board of directors (the “Board”); (2) the ratification of the appointment of UHY LLP as the Company’s independent registered public accounting firm; (3) an amendment to the Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to enable a potential reverse split of the issued and outstanding shares of Common Stock at a ratio of up to 1-for-20, with such ratio to be determined at the sole discretion of the Board and with such reverse split to be effected at such time and date on or before December 31, 2021, if at all, as determined by the Board in its sole discretion (the “Reverse Split Proposal”); (4)the adoption of an amendment to the Certificate of Incorporation, to, among other things, decrease the Company’s authorized common stock from 3,000,000,000 shares to 500,000,000 shares (the “Charter Proposal”); (5) the adoption of an amendment to the Company’s Certificate of Designation of the Series F preferred stock to increase the number of authorized shares from 1,500 to 4,000 with such increase to be determined at the sole discretion of the Board and with such increase to be effected at such time and date on or before December 31, 2021, if at all, as determined by the Board in its sole discretion (the “Series F Increase”); (6) the approval, on an advisory basis, of the compensation of our named executive officers (“Compensation of Executive Officers”); and (7) approval of the frequency of conducting future stockholder advisory votes on the compensation of named executive officers, the options being one year, two years or three years (“Frequency Proposal”).

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2021
SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants.
Principles of Consolidation	The accompanying consolidated financial statements include the accounts of Guided Therapeutics, Inc. and its wholly owned subsidiary. All intercompany transactions are eliminated.
Accounting Standards Update	In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740)”. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and by clarifying and amending other areas of Topic 740. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2020. We adopted this ASU on January 1, 2021 with no material impact on our consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders’ equity to liabilities as it relates to the Company’s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS), which is consistent with the Company’s accounting treatment under the current standard. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. The Company has early adopted ASU No. 2020-06 under a modified retrospective basis on January 1, 2021. The result of the early adoption would have been a change to retained earnings of $102,000 for the year ended December 31, 2020. Except as noted above, the guidance issued by the FASB during the current year is not expected to have a material effect on the Company’s consolidated financial statements. A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements.
Cash Equivalents	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
Accounts Receivable	The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility, is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable.
Concentrations of Credit Risk	The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
Inventory Valuation	All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. At June 30, 2021 and December 31, 2020, our inventories were as follows (in thousands): June 30, December 31, 2021 2020 Raw materials $ 1,286 $ 1,276 Work in process 81 80 Finished goods 22 7 Inventory reserve (758 ) (758 ) Total $ 631 $ 605 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.
Property and Equipment	Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at June 30, 2021 and December 31, 2020 (in thousands): June 30, December 31, 2021 2020 Equipment $ 1,048 $ 1,042 Software 652 652 Furniture and fixtures 41 41 Leasehold improvement 12 12 1,753 1,747 Less accumulated depreciation and amortization (1,746 ) (1,746 ) Total $ 7 $ 1 During the six months ended June 30, 2021 and year ended December 31, 2020, the Company disposed of approximately nil and $647,000 of property and equipment that was fully depreciated, respectively.
Debt Issuance Costs	Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount.
Patent Costs (Principally Legal Fees)	Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs aggregated approximately $10,000 and $4,000 for the six months ended June 30, 2021 and 2020, respectively.
Leases	With the implementation of ASU 2016-02, “Leases (Topic 842)”, the Company recorded a lease-right-of-use asset and a lease liability. The Company adopted the standard on January 1, 2019. The implementation required the analysis of certain criteria in determining its treatment. The Company determined that its corporate office lease met those criteria. The Company implemented the guidance using the alternative transition method. Under this alternative, the effective date would be the date of initial application. See Note 7: Commitments and Contingencies
Accrued Liabilities	Accrued liabilities are summarized as follows (in thousands): June 30, 2021 December 31, 2020 Compensation $ 781 $ 1,094 Professional fees 28 83 Subscription receivable 350 - Interest 138 1,517 Vacation 43 34 Preferred dividends 347 202 Other accrued expenses 44 65 Total $ 1,731 $ 2,995
Subscription Receivables	Cash received from investors for common stock shares that has not completed processing is recorded as a liability to subscription receivables. As of June 30, 2021, the Company had received $350,000 from Mr. Blumberg.
Revenue Recognition	The Company follows, ASC 606 Revenue from Contracts with Customers establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and, the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company had $2,000 and nil in revenues for the six months ended June 30, 2021 and 2020.
Significant Distributors	As of June 30, 2021, accounts receivable outstanding was $152,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $26,000 which was from two distributors. As of December 31, 2020, accounts receivable outstanding was $150,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $24,000 which was from one distributor.
Deferred Revenue	The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of June 30, 2021, and December 31, 2020, the Company had $62,000 and $42,000in deferred revenue, respectively.
Research and Development	Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.
Income Taxes	The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management provides valuation allowances against the deferred tax assets for amounts that are not considered more likely than not to be realized. The Company has filed its 2020 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At December 31, 2020, the Company has approximately $61.6 million of net operating losses carryforward available. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The current corporate tax rate in the U.S. is 21%.
Uncertain Tax Positions	The Company assesses each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At December 31, 2020 and, 2019, there were no uncertain tax positions. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia.
Warrants	The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.
Stock Based Compensation	The Company records compensation expense related to options granted to employees and non-employees based on the fair value of the award. Compensation cost is recorded as earned for all unvested stock options outstanding at the beginning of the first year based upon the grant date fair value estimates, and for compensation cost for all stock based payments granted or modified subsequently based on fair value estimates. On July 14, 2020, the Company granted stock options to employees and consultants. The new Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. Stock options granted have a 10-year life and expire 90 days after employment or upon termination of consulting agreement. Vesting schedule varies per grantee. Generally stock options granted vest as follows: 25% vest immediately, and the remaining stock options vest over 33 months, beginning three months after grant. For the six months ended June 30, 2021 and 2020 share-based compensation for options attributable to employees, non-employees, officers and Board members were approximately $122,000 and nil, respectively. These amounts have been included in the Company’s statements of operations under general and administrative expense. Compensation costs for stock options which vest over time are recognized over the vesting period. As of June 30, 2021, and 2020 the Company had approximately $450,000 and nil of unrecognized compensation costs related to granted stock options that will be recognized, respectively.
Beneficial Conversion Features of Convertible Securities	The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of January 1, 2020. In doing so, warrants with a down round feature previously treated as a derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Conversion options that are not bifurcated as a derivative pursuant to ASC 815 and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether they are beneficial to the investor at inception (a beneficial conversion feature) or may become beneficial in the future due to potential adjustments. The beneficial conversion feature guidance in ASC 470-20 applies to convertible stock as well as convertible debt which are outside the scope of ASC 815. A beneficial conversion feature is defined as a nondetachable conversion feature that is in the money at the commitment date. The beneficial conversion feature guidance requires recognition of the conversion option’s in-the-money portion, the intrinsic value of the option, in equity, with an offsetting reduction to the carrying amount of the instrument. The resulting discount is amortized as a dividend over either the life of the instrument, if a stated maturity date exists, or to the earliest conversion date, if there is no stated maturity date. If the earliest conversion date is immediately upon issuance, the dividend must be recognized at inception. When there is a subsequent change to the conversion ratio based on a future occurrence, the new conversion price may trigger the recognition of an additional beneficial conversion feature on occurrence. The Company also adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt.
Derivatives	The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2021
SIGNIFICANT ACCOUNTING POLICIES
Inventory valuation	June 30, December 31, 2021 2020 Raw materials $ 1,286 $ 1,276 Work in process 81 80 Finished goods 22 7 Inventory reserve (758 ) (758 ) Total $ 631 $ 605
Property and equipment	June 30, December 31, 2021 2020 Equipment $ 1,048 $ 1,042 Software 652 652 Furniture and fixtures 41 41 Leasehold improvement 12 12 1,753 1,747 Less accumulated depreciation and amortization (1,746 ) (1,746 ) Total $ 7 $ 1
Accrued liabilities	June 30, 2021 December 31, 2020 Compensation $ 781 $ 1,094 Professional fees 28 83 Subscription receivable 350 - Interest 138 1,517 Vacation 43 34 Preferred dividends 347 202 Other accrued expenses 44 65 Total $ 1,731 $ 2,995

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
	Jun. 30, 2021
FAIR VALUE OF FINANCIAL INSTRUMENTS
Schedule fo fair value for liabilities measured on a recurring basis	Fair Value at June 30, 2021 Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 - - (29 ) (29 ) Total long-term liabilities at fair value $ - $ - $ (29 ) $ (29 ) Fair Value at December 31, 2020 Level 1 Level 2 Level 3 Total Warrants issued in connection with Senior Secured Debt - - (2,203 ) (2,203 ) Derivative liability/bifurcated conversion option in connection with Auctus $1,100,000 loan on December 17, 2019 - - (25 ) (25 ) Total long-term liabilities at fair value $ - $ - $ (2,228 ) $ (2,228 )
Summary of changes to Level 3 instruments	Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Senior Secured Debt Derivative Total Balance, December 31, 2020 $ (2,203 ) $ (25 ) $ (2,228 ) Change in the terms of warrants previously recorded as a liability and now reclassified to equity 1,755 - 1,755 Change in value due to warrants expiring during the year 448 - 448 Extinguishment of derivative liability due to payoff of $700,000 loan to Auctus 84 84 Change in fair value during the year - (88 ) (88 ) Balance, June 30, 2021 $ - $ (29 ) $ (29 )

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	6 Months Ended
	Jun. 30, 2021
STOCKHOLDERS' DEFICIT:
Common stock issued	Shares issued for payments of Series D dividends 60,598 Shares issued for payment of finder fee 98,000 Issued during the six months ended June 30, 2021 158,598 Balance at December 31, 2020 13,138,282 Issued in 2021 158,598 Balance at June 30, 2021 13,296,880
Debt exchanges	Total Debt and Accrued Interest Total Debt Total Accrued Interest Common Stock Shares Warrants (Exercise $0.25) Warrants (Exercise $0.75) Warrants (Exercise $0.20) Warrants (Exercise $0.15) Warrants (Exercise $0.50) Aquarius $ 145,544 $ 107,500 $ 38,044 291,088 145,544 145,544 - - - K2 Medical (Shenghuo) 3 803,653 771,927 31,726 1,905,270 704,334 704,334 496,602 - - Mr. Blumberg 305,320 292,290 13,030 1,167,630 119,656 119,656 928,318 - - Mr. Case 179,291 150,000 29,291 896,456 - - 896,456 - - Mr. Grimm 51,110 50,000 1,110 255,548 - - 255,548 - - Mr. Gould 111,227 100,000 11,227 556,136 - - 556,136 - - Mr. Mamula 15,577 15,000 577 77,885 - - 77,885 - - Dr. Imhoff 2 400,417 363,480 36,937 1,699,255 100,944 100,944 1,497,367 - - Ms. Rosenstock 1 50,000 50,000 - 100,000 50,000 50,000 - - - Mr. James 2 2,286 2,000 286 7,745 1,227 1,227 5,291 - - Auctus 328,422 249,119 79,303 500,000 - - - 700,000 - Mr. Clavijo 125,000 125,000 - 500,000 - - - - 500,000 Mr. Wells 4 220,000 220,000 - - - - - - - $ 2,737,847 $ 2,496,316 $ 241,531 7,957,013 1,121,705 1,121,705 4,713,603 700,000 500,000
Outstanding warrants	Warrants (Underlying Shares) Outstanding, January 1, 2021 28,324,275 Issuances 3,437,300 Canceled / Expired (1,729,662 ) Exercised - Outstanding, June 30, 2021 30,031,913
Shares reserved for warrants	Warrants Exercise Price Expiration Date 7,185,000 (1) $0.20 per share February 12, 2023 325,000 (2) $0.18 per share April 4, 2022 215,000 (3) $0.25 per share July 1, 2022 100,000 (4) $0.25 per share September 1, 2022 7,500,000 (5) $0.20 per share December 17, 2024 250,000 (6) $0.16 per share March 31, 2025 2,597,705 (7) $0.25 per share December 30, 2022 2,597,705 (8) $0.75 per share December 30, 2022 4,713,603 (9) $0.20 per share December 30, 2022 59,600 (10) $0.25 per share April 23, 2023 50,000 (11) $0.25 per share December 30, 2022 50,000 (12) $0.75 per share December 30, 2022 700,000 (13) $0.15 per share May 21, 2023 250,000 (14) $0.50 per share June 23, 2023 1,000 (15) $0.50 per share August 10, 2022 1,250,000 (16) $0.25 per share February 22, 2023 196,000 (17) $0.25 per share March 3, 2024 239,950 (18) $0.25 per share May 5, 2024 207,750 (19) $0.50 per share May 5, 2024 1,130,000 (20) $0.80 per share May 17, 2023 200,000 (21) $0.50 per share May 31, 2023 63,600 (22) $0.80 per share May 31, 2023 150,000 (23) $0.50 per share May 31, 2024 30,031,913

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	6 Months Ended
	Jun. 30, 2021
STOCK OPTIONS
Stock options granted	Stock options vested 892,977 Stock options unvested 932,023 Total stock options granted at June 30, 2021 1,825,000
Stock option activity	Shares Weighted Average Exercise Price Outstanding at beginning of year 1,800,000 $ 0.49 Options granted 25,000 0.49 Options exercised - - Options expired/forfeited - - Outstanding at end of the period 1,825,000 $ 0.49

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2021
COMMITMENTS & CONTINGENCIES (Note 7)
Future minimum rental payments under non-cancellable operating leases	Year Amount 2021 $ 62 2022 108 2023 112 2024 115 2025 118 Thereafter 50 Total 565 Less: Interest 146 Present value of lease liability $ 419

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2021
NOTES PAYABLE
Notes payable in default, including related parties	June 30, 2021 December 31, 2020 Mr. Mermelstein $ 308 $ 285 Dr. Cartwright - 1 Mr. Fowler - 26 GPB - 17 Notes payable in default $ 308 $ 329
Short-term notes payable, including related parties	June 30, 2021 December 31, 2020 Dr. Cartwright $ 41 $ 46 Dr. Faupel 5 5 Mr. Fowler 19 - Premium Finance (insurance) - 45 Short-term notes payable, including related parties $ 65 $ 96

SHORT-TERM CONVERTIBLE DEBT (Ta

SHORT-TERM CONVERTIBLE DEBT (Tables)	6 Months Ended
	Jun. 30, 2021
SHORT-TERM CONVERTIBLE DEBT
Convertible notes payable	June 30, 2021 December 31, 2020 Auctus Tranche 2 (December 17, 2019 note) $ 400 $ 400 Auctus prepayment penalty (December 17, 2019 note) 350 - Auctus Tranche 1 (December 17, 2019 note) - 700 Auctus (March 31, 2020 note) - 113 Debt discount and issuance costs to be amortized (30 ) (262 ) Convertible notes payable – short-term $ 720 $ 951

CONVERTIBLE DEBT (Tables)

CONVERTIBLE DEBT (Tables)	6 Months Ended
	Jun. 30, 2021
SHORT-TERM CONVERTIBLE DEBT
Convertible notes in default	June 30, 2021 December 31, 2020 GPB $ - $ - $ 1,709 $ 1,709 GHS - 64 - 14 - - 103 181 Auctus 169 169 - 40 Convertible notes, past due (including debt in default) $ 169 $ 1,930

LONG TERM DEBT (Tables)

LONG TERM DEBT (Tables)	6 Months Ended
	Jun. 30, 2021
LONG TERM DEBT
Long-term debt, related parties	Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange $ 661 Amount forgiven (454 ) Total Interest accrued through December 31, 2020 29 Balance outstanding at December 31, 2020 $ 236 Exchange for Series F-2 Preferred Stock (85 ) Interest accrued through June 30, 2021 7 Balance outstanding at June 30, 2021 $ 158 Salary $ 337 Bonus 675 Interest on compensation 528 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange $ 1,621 Amount forgiven (1,302 ) Total Interest accrued through December 31, 2020 45 Balance outstanding at December 31, 2020 $ 364 Exchange for Series F-2 Preferred Stock (100 ) Interest accrued through June 30, 2021 7 Balance outstanding at June 30, 2021 $ 271
Long-term debt, related parties debt obligations	Year Amount 2021 $ - 2022 - 2023 462 2024 43 2025 43 Thereafter 31 Totals $ 579

INCOME (LOSS) PER COMMON SHARE

INCOME (LOSS) PER COMMON SHARE (Tables)	6 Months Ended
	Jun. 30, 2021
INCOME (LOSS) PER COMMON SHARE
Earnings per share	In thousands June 30, 2021 2020 Net loss $ (1,871 ) $ (4,049 ) Basic weighted average number of shares outstanding 13,226 8,463 Net loss per share (basic) $ (0.14 ) $ (0.48 ) Diluted weighted average number of shares outstanding 13,226 8,463 Net loss per share (diluted) $ (0.14 ) $ (0.48 ) Dilutive equity instruments (number of equivalent units): Stock options - - Preferred stock 18,316 - Convertible debt 1,281 31,228 Warrants 17,869 5,341 Total Dilutive instruments 37,466 36,569

ORGANIZATION, BACKGROUND, AND_2

ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Common stock, outstanding (in thousands)	13,297		13,138
Working capital	$ (4)
Accumulated deficit	141.8
Net income (loss)	1.9
Total stockholders' deficits	$ 5.3
Warrants [Member] | Minimum
Warrants exercise price per share	$ 0.15
Warrants [Member] | Maximum
Warrants exercise price per share	$ 0.80
Warrants [Member] | Exchange Agreement With GPB [Member]
Warrants exercisable for common stock outstanding	30,100,000
Proceeds from exercise of warrants	$ 5.7
Subsequent Event | 10% Convertible Debentures
Proceeds from sale of stocks		$ 1.1
Series F, Series F-2 and G Preferred Stock | Subsequent Event
Proceeds from sale of stocks		$ 2.1

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
SIGNIFICANT ACCOUNTING POLICIES
Raw materials	$ 1,286	$ 1,276
Work in process	81	80
Finished goods	22	7
Inventory reserve	(758)	(758)
Total	$ 631	$ 605

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property and equipment, gross	$ 1,753	$ 1,747
Less accumulated depreciation and amortization	(1,746)	(1,746)
Property and equipment, net	7	1
Furniture and Fixtures
Property and equipment, gross	41	41
Equipment
Property and equipment, gross	1,048	1,042
Software
Property and equipment, gross	652	652
Leasehold Improvement
Property and equipment, gross	$ 12	$ 12

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
SIGNIFICANT ACCOUNTING POLICIES
Compensation	$ 781	$ 1,094
Professional fees	28	83
Subscritpion receivable	350	0
Interest	138	1,517
Vacation	43	34
Preferred dividends	347	202
Other accrued expenses	44	65
Total	$ 1,731	$ 2,995

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Jul. 14, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
SIGNIFICANT ACCOUNTING POLICIES
Disposal of property and equipment		$ 0		$ 647,000,000
Retained earnings				102,000
Uncertain tax positions				0	$ 0
Patent costs		10,000,000	$ 4,000,000
Subscription receivable		350,000,000
Accounts receivable outstanding		152,000,000		150,000,000
Accounts receivable, net of allowance		126,000,000		126,000,000
Revenues others		2,000	0
Deferred revenue		$ 62,000,000		42,000,000
Net operating loss carry forward				61,600,000
Corporate tax rate		21.00%
Stock options granted vesting percentage		25.00%
Stock options vesting period		33 years
Stock options granted expiry period	10 years	10 years
Share-based compensation			$ 0
Unrecognized compensation costs		$ 450,000,000		$ 0

FAIR VALUE OF FINANCIAL INSTR_3

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Derivative liability	$ (29,000)	$ (2,228,000)
Auctus Loan
Derivative liability	(29,000)	(25,000)
Senior Secured Debt
Derivative liability		(2,203,000)
Level 1
Derivative liability	0	0
Level 1 | Auctus Loan
Derivative liability	0	0
Level 1 | Senior Secured Debt
Derivative liability		0
Level 2
Derivative liability	0	0
Level 2 | Auctus Loan
Derivative liability	0	0
Level 2 | Senior Secured Debt
Derivative liability		0
Level 3
Derivative liability	$ (29,000)	(2,228,000)
Level 3 | Senior Secured Debt
Derivative liability		$ (2,203,000)

FAIR VALUE OF FINANCIAL INSTR_4

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Change in fair value during the year	$ 0	$ 2,200,000
Level 3
Beginning Balance, Warrants	(25)
Change in the terms of warrants previously recorded as a liability now reclassified to equity	1,755,000
Change in value due to warrants expiring during the year	448,000
Change in fair value during the year	(88,000)
Ending Balance, Warrants	(29)
Senior Secured Debt | Level 3
Beginning Balance, Warrants	(2,203)
Change in the terms of warrants previously recorded as a liability now reclassified to equity	1,755,000
Change in value due to warrants expiring during the year	448,000
Change in fair value during the year	0
Ending Balance, Warrants	(29)
Derivative | Level 3
Beginning Balance, Warrants	(2,228)
Change in the terms of warrants previously recorded as a liability now reclassified to equity	0
Change in value due to warrants expiring during the year	0
Change in fair value during the year	(88,000)
Ending Balance, Warrants	$ 0

FAIR VALUE OF FINANCIAL INSTR_5

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	Dec. 17, 2019	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
FAIR VALUE OF FINANCIAL INSTRUMENTS
Payment for derivative liability		$ 700,000	$ 1,100,000
Fair value of derivative liability		29,000	29,000		$ 25,000
Derivative liability/bifurcated conversion option in connection with auctus loan	$ 1,100,000
Extinguishment of derivative liability due to payoff of loan to Auctus		700,000	700,000
Fair value of warrants			0	$ 2,200,000
Net change in derivative liability			2,200,000
Derivative liability		$ 400,000	$ 400,000

STOCKHOLDERS DEFICIT (Details)

STOCKHOLDERS DEFICIT (Details)	6 Months Ended
	Jun. 30, 2021shares
STOCKHOLDERS' DEFICIT:
Shares issued for payment of Series D dividends	60,598
Shares issued for payment of finder fee	98,000
Issued during the six months ended June 30, 2021	158,598
Balance, shares	13,138,282
Issued in 2021	158,598
Balance, shares	13,296,880

STOCKHOLDERS DEFICIT (Details 1

STOCKHOLDERS DEFICIT (Details 1) - USD ($)	1 Months Ended	6 Months Ended
	Feb. 19, 2021	Jun. 30, 2021
Total debt and accrued interest		$ 2,737,847,000
Total debt		2,496,316,000
Total accrued interest		$ 241,531,000
Common stock shares	2,236	7,957,013
Warrants (exercise $0.25)		1,121,705
Warrants (exercise $0.75)		1,121,705
Warrants (exercise $0.20)		4,713,603
Warrants (Exercise $0.15)		700,000
Warrants (Exercise $0.50)		500,000
Auctus
Total debt and accrued interest		$ 328,422,000
Total debt		249,119,000
Total accrued interest		$ 79,303,000
Common stock shares		500,000
Warrants (exercise $0.25)		0
Warrants (exercise $0.75)		0
Warrants (exercise $0.20)		0
Warrants (Exercise $0.15)		700,000
Warrants (Exercise $0.50)		0
Mr. Blumberg
Total debt and accrued interest		$ 305,320,000
Total debt		292,290,000
Total accrued interest		$ 13,030,000
Common stock shares		1,167,630
Warrants (exercise $0.25)		119,656
Warrants (exercise $0.75)		119,656
Warrants (exercise $0.20)		928,318
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0
Ms. Rosenstock
Total debt and accrued interest		$ 50,000,000
Total debt		50,000,000
Total accrued interest		$ 0
Common stock shares		100,000
Warrants (exercise $0.25)		50,000
Warrants (exercise $0.75)		50,000
Warrants (exercise $0.20)		0
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0
Aquarius
Total debt and accrued interest		$ 145,544,000
Total debt		107,500,000
Total accrued interest		$ 38,044,000
Common stock shares		291,088
Warrants (exercise $0.25)		145,544
Warrants (exercise $0.75)		145,544
Warrants (exercise $0.20)		0
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0
K2 Medical (Shenghuo)
Total debt and accrued interest		$ 803,653,000
Total debt		771,927,000
Total accrued interest		$ 31,726,000
Common stock shares		1,905,270
Warrants (exercise $0.25)		704,334
Warrants (exercise $0.75)		704,334
Warrants (exercise $0.20)		496,602
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0
Mr. Case
Total debt and accrued interest		$ 179,291,000
Total debt		150,000,000
Total accrued interest		$ 29,291,000
Common stock shares		896,456
Warrants (exercise $0.25)		0
Warrants (exercise $0.75)		0
Warrants (exercise $0.20)		896,456
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0
Mr. Grimm
Total debt and accrued interest		$ 51,110,000
Total debt		50,000,000
Total accrued interest		$ 1,110,000
Common stock shares		255,548
Warrants (exercise $0.25)		0
Warrants (exercise $0.75)		0
Warrants (exercise $0.20)		255,548
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0
Mr. Gould
Total debt and accrued interest		$ 111,227,000
Total debt		100,000,000
Total accrued interest		$ 11,227,000
Common stock shares		556,136
Warrants (exercise $0.25)		0
Warrants (exercise $0.75)		0
Warrants (exercise $0.20)		556,136
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0
Mr. Mamula
Total debt and accrued interest		$ 15,577,000
Total debt		15,000,000
Total accrued interest		$ 577,000
Common stock shares		77,885
Warrants (exercise $0.25)		0
Warrants (exercise $0.75)		0
Warrants (exercise $0.20)		77,885
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0
Dr. Imhoff
Total debt and accrued interest		$ 400,417,000
Total debt		363,480,000
Total accrued interest		$ 36,937,000
Common stock shares		1,699,255
Warrants (exercise $0.25)		100,944
Warrants (exercise $0.75)		100,944
Warrants (exercise $0.20)		1,497,367
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0
Mr. James
Total debt and accrued interest		$ 2,286,000
Total debt		2,000,000
Total accrued interest		$ 286,000
Common stock shares		7,745
Warrants (exercise $0.25)		1,227
Warrants (exercise $0.75)		1,227
Warrants (exercise $0.20)		5,291
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0
Mr. Clavijo
Total debt and accrued interest		$ 125,000,000
Total debt		125,000,000
Total accrued interest		$ 0
Common stock shares		500,000
Warrants (exercise $0.25)		0
Warrants (exercise $0.75)		0
Warrants (exercise $0.20)		0
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		500,000
Mr. Wells
Total debt and accrued interest		$ 220,000,000
Total debt		220,000,000
Total accrued interest		$ 0
Common stock shares		0
Warrants (exercise $0.25)		0
Warrants (exercise $0.75)		0
Warrants (exercise $0.20)		0
Warrants (Exercise $0.15)		0
Warrants (Exercise $0.50)		0

STOCKHOLDERS DEFICIT (Details 2

STOCKHOLDERS DEFICIT (Details 2)	6 Months Ended
	Jun. 30, 2021shares
STOCKHOLDERS' DEFICIT:
Warrants outstanding, beginning	28,324,275
Issuances	3,437,300
Canceled/expired	1,729,662
Exercised	0
Warrants outstanding, ending	30,031,913

STOCKHOLDERS DEFICIT (Details 3

STOCKHOLDERS DEFICIT (Details 3) - $ / shares	6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Warrants outstanding, beginning	30,031,913	28,041,013	28,324,275
Warrants 1
Warrants outstanding, beginning	7,185,000
Warrants exercise price	$ 0.20
Expiration date	February 12, 2023
Warrants 2
Warrants outstanding, beginning	325,000
Warrants exercise price	$ 0.18
Expiration date	April 4, 2022
Warrants 3
Warrants outstanding, beginning	215,000
Warrants exercise price	$ 0.25
Expiration date	July 1, 2022
Warrants 4
Warrants outstanding, beginning	100,000
Warrants exercise price	$ 0.25
Expiration date	September 1, 2022
Warrants 5
Warrants outstanding, beginning	7,500,000
Warrants exercise price	$ 0.20
Expiration date	December 17, 2024
Warrants 6
Warrants outstanding, beginning	250,000
Warrants exercise price	$ 0.16
Expiration date	March 31, 2025
Warrants 7
Warrants outstanding, beginning	2,597,705
Warrants exercise price	$ 0.25
Expiration date	December 30, 2022
Warrants 8
Warrants outstanding, beginning	2,597,705
Warrants exercise price	$ 0.75
Expiration date	December 30, 2022
Warrant 9
Warrants outstanding, beginning	4,713,603
Warrants exercise price	$ 0.20
Expiration date	December 30, 2022
Warrant 10
Warrants outstanding, beginning	59,600
Warrants exercise price	$ 0.25
Expiration date	April 23, 2023
Warrant 11
Warrants outstanding, beginning	50,000
Warrants exercise price	$ 0.25
Expiration date	December 30, 2022
Warrant 12
Warrants outstanding, beginning	50,000
Warrants exercise price	$ 0.75
Expiration date	December 30, 2022
Warrant 13
Warrants outstanding, beginning	700,000
Warrants exercise price	$ 0.15
Expiration date	May 21, 2023
Warrant 14
Warrants outstanding, beginning	250,000
Warrants exercise price	$ 0.50
Expiration date	June 23, 2023
Warrant 15
Warrants outstanding, beginning	1,000
Warrants exercise price	$ 0.50
Expiration date	August 10, 2022
Warrant 16
Warrants outstanding, beginning	1,250,000
Warrants exercise price	$ 0.25
Expiration date	February 22, 2023
Warrant 17
Warrants outstanding, beginning	196,000
Warrants exercise price	$ 0.25
Expiration date	March 3, 2024
Warrant 18
Warrants outstanding, beginning	239,950
Warrants exercise price	$ 0.25
Expiration date	May 5, 2024
Warrant 19
Warrants outstanding, beginning	207,750
Warrants exercise price	$ 0.50
Expiration date	May 5, 2024
Warrant 20
Warrants outstanding, beginning	1,130,000
Warrants exercise price	$ 0.80
Expiration date	May 17, 2023
Warrant 21
Warrants outstanding, beginning	200,000
Warrants exercise price	$ 0.50
Expiration date	May 31, 2023
Warrant 22
Warrants outstanding, beginning	63,600
Warrants exercise price	$ 0.80
Expiration date	May 31, 2023
Warrant 23
Warrants outstanding, beginning	150,000
Warrants exercise price	$ 0.50
Expiration date	May 31, 2024

STOCKHOLDERS DEFICIT (Details N

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)	Mar. 10, 2021	Jul. 14, 2020	Jul. 09, 2020	Jun. 03, 2020	Jan. 08, 2020	May 03, 2016	Mar. 22, 2021	Feb. 28, 2021	Jan. 31, 2021	Jan. 16, 2021	Aug. 31, 2018	Jun. 30, 2021	Jun. 30, 2020	Apr. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Feb. 24, 2021	Feb. 19, 2021	Jan. 08, 2021
Common stock, par value												$ 0.001			$ 0.001			$ 0.001
Common stock, authorized public shares												3,000,000,000			3,000,000,000			3,000,000,000
Common stock, issued public shares						29						13,296,880			13,296,880			13,138,282
Common stock, outstanding												13,297			13,297			13,138
Preferred stock shares authorized												5,000,000			5,000,000
Preferred stock shares par value												$ 0.001			$ 0.001
Issued during the six months ended June 30, 2021															158,598
Debt exchanged for equity instruments fair value												$ 2,737,847,000			$ 2,737,847,000
Fair value of extinguishment of debt															$ 1,808,712
Common share stock options vest exercise price															$ 0
Debt												$ 2,496,316,000			$ 2,496,316,000
Shares exchange												13,296,880			13,296,880			13,138,282	13,180,417
Common stock warrants		1,800,000													1,825,000
Common stock issued during period															98,000
Preferred stock dividends accrued												$ 125,000	$ 17,000		$ 177,000	$ 29,000
Investments | Subsequent Event
Common stock, issued public shares																	98,000
Warrants for common stock shares equity																	643,700
Total investment amount																	$ 2,114,000
Warrants to purchase common stock shares																	1,130,000
Equity investments fee																	$ 139,000
Proceeds from debenture unit investments																	1,130,000
Debenture fee																	$ 86,400
Debentures convertible into common stock shares																	2,260,000
Warrants [Member] | Exchange Agreement With GPB [Member]
Purchase of common stock shares										35,937,500
Purchase price										$ 0.04
Warrant purchase shares										7,185,000
Warrant price										$ 0.20
Final payment of warrant										$ 750,000
Warrants to purchase common stock shares												30,100,000			30,100,000
Maximum | Warrants [Member]
Warrants to purchase common stock shares exercise price												$ 0.80			$ 0.80
Ms. Rosenstock
Debt exchanged for equity instruments fair value												$ 50,000,000			$ 50,000,000
Debt												50,000,000			50,000,000
Mr. Blumberg
Debt exchanged for equity instruments fair value												305,320,000			305,320,000
Debt												292,290,000			292,290,000
Dr. Faupel
Forgive repayment amount																		$ 454,000
Short-term note												158,000			158,000			236,000
Dr. Cartwright
Forgive repayment amount																		1,302,000
Short-term note												$ 271,000			$ 271,000			364,000
Debt Exchanges - 2020
Common stock, issued public shares				500,000								500,000			500,000
Outstanding debt			$ 220,000															40,000
Forgive repayment amount			110,000		$ 29,000
Debt exchanged for equity instruments				$ 328,422	2,064,366
Debt exchanged for equity instruments fair value					2,065,548
Gain/Loss on extinguishment of debts				$ 118,396	$ 1,183										$ 224,963			20,000
Warrants for common stock shares equity				700,000	6,957,013							250,000			250,000
Common stock, issued fair value				$ 250,000
Common stock, issued price per share				$ 0.50
Warrants to purchase common stock black scholes fair valuation				196,818								99,963			99,963
Warrants to purchase common stock black scholes fair valuation exercise price				$ 0.281								$ 0.40			$ 0.40
Fair value of extinguishment of debt				$ 446,818											$ 349,963
Extinguishment of exchange debt				$ 328,422											125,000
Short-term note												$ 125,000			$ 125,000
Warrant exercise price per share															0.50
Exchange transaction remaining balance															$ 10,213
Cash payments			20,000															$ 20,000
Unsecured note			$ 90,000
Maturity term			18 months
Common share stock options vest			66,000
Common share stock options vest exercise price			$ 0.49
Common share stock options vesting rate			$ 3.667
Bearing interest rate percentage			6.0
Debt Exchanges - 2020 | Ms. Rosenstock
Forgive repayment amount															$ 28,986
Debt Exchanges - 2021
Common stock, issued public shares												2,236			2,236			13,138,282
Debt																						$ 1,500,000
Debt final payment																						$ 750,000
Debt Exchanges - 2021 | Mr. Fowler
Preferred stock shares converts into common stock							200,000
Short-term note							$ 26,400
Unsecured note							150,000
Deferred salary							412,624
Accrued interest							133,590
Total Compensation							546,214
Exchanged amount							50,000
Amount owed							$ 546,214
Shares exchange							50
Accrues interest rate, percentage							6.00%
Monthly installments							$ 3,600
Monthly installments period term							4 years
short-term note accrued interest							$ 18,718
Debt Exchanges - 2021 | Mr. Fowler | Maximum
Forgive repayment amount							86,554
Debt Exchanges - 2021 | Mr. Blumberg
Shares exchange	88
Consulting fees	$ 88,000
Debt Exchanges - 2021 | Dr. Faupel
Shares exchange																					100
Long-term debt																					$ 100,000
Debt Exchanges - 2021 | Dr. Cartwright
Shares exchange																					85
Long-term debt																					$ 85,000
Series C Convertible Preferred Shares
Preferred stock shares authorized												9			9			9
Preferred stock shares par value												$ 0.001			$ 0.001			$ 0.001
Preferred stock shares outstanding												286			286
Preferred stock shares designated												9,000			9,000
Conversion price per share															$ 0.50
Preferred stock shares converts into common stock											2,000				2,000			2,000
Total convertible of common stock shares											6,524,500				572,000
Convertible of common stock shares description															The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt.
Liquidation preference												$ 1,000			$ 1,000
Exercise price per share, amount															$ 512,000
Preferred stock shares surrendered						1,916
Series C1 Convertible Preferred Shares
Preferred stock shares outstanding												1,050			1,050			1,050
Conversion price per share															$ 0.50			$ 0.50
Preferred stock shares converts into common stock															2,000			2,000
Total convertible of common stock shares															2,098,500			2,098,500
Preferred stock shares surrendered											326,225				3,262,225
Preferred stock shares issued						4,312						1,050			1,050			1,050
Shares outstanding												104,925			104,925			1,024,925
Series C2 Convertible Preferred Shares
Conversion price per share											$ 0.50				$ 0.50			$ 0.50
Total convertible of common stock shares															2,000			2,000
Preferred stock shares surrendered											326,225				326,225
Preferred stock shares issued											326,225
Series G Convertible Preferred Shares
Preferred stock shares authorized												1,000			1,000			1,000
Preferred stock shares par value												$ 0.001			$ 0.001			$ 0.001
Preferred stock shares outstanding												0			0		62,000	0
Convertible preferred stock description															uring January 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $78,500, net to the Company is $75,000, for 91,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred.
Convertible preferred stock description 1															During February 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $53,500, net to the Company is $50,000, for 62,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. Due to the mandatory redemption feature of the Series G preferred stock, the total amount of proceeds of $125,000 was recorded as a liability. On June 4, 2021, the Company redeemed the January 2021 investment of $75,000 for $114,597, this $39,597 difference was recorded as interest expense. As of June 30, 2021, the amount outstanding was $50,000 and is presented as a liability. As of June 30, 2021, the Company has also accrued dividends of $1,915.
Preferred stock shares issued												62			62			0
Preferred stock shares received																	153,000
Investment net																	$ 132,000
Investment net																	$ 125,000
Preferred stock redeemed																	91,000
Series G Convertible Preferred Shares | Power Up Lending Group Ltd [Member]
Additional Series G preferred stock shares								62,000	91,000
Investment net								$ 53,500	$ 78,500
Additional Series G preferred stock shares, amount								50,000	75,000
Financing cost								$ 925,000	$ 925,000
Discounted rate								19.00%	19.00%
Conversion beneficial ownership limitation								4.99%	4.99%
Increased election holders								9.99%	9.99%
Cumulative dividends rate								8.00%	8.00%
Corresponding percentage Description								Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%.	Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%.
Net proceeds															$ 125,000
Total investment amount												$ 75,000			75,000
Outstanding amount												50,000			50,000
Accrued Value												$ 1,915			1,915
Difference of interest expense															$ 39,597
Series F-2 Convertible Preferred Shares
Preferred stock shares authorized												5			5			5
Preferred stock shares par value												$ 0.001			$ 0.001			$ 0.001
Preferred stock shares outstanding												3,237			3,237
Preferred stock shares designated												5,000			5,000
Preferred stock shares converts into common stock															4,000
Liquidation preference												$ 3,339			$ 3,339
Convertible preferred stock description															Board designated 5,000 shares of preferred stock as Series F-2 Preferred Stock, 3,237 of which are issued and outstanding. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F-2 Investors”). In total, for $678,000 the Company issued 678 shares of Series F-2 Preferred Stock. In addition, the Company exchanged outstanding debt of $2,559,000 for 2,559 shares of Series F-2 Preferred Stock. Each Series F-2 Preferred Stock is convertible into 4,000 common stock shares. The Series F-2 Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value and liquidation preference on the Series F-2 Preferred Stock is $3,339. Below is a summary of the debt exchanges. On March 22, 2021, the Company exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Shares (convertible into 200,000 common stock shares), a $150,000 unsecured note and Mr. Fowler will remain on our health insurance plan. Mr. Fowler forgave $86,554 and may forgive up to $259,661 if the Company complies with the repayment plan.
Convertible preferred stock description 1															On March 22, 2021, the Company exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Shares (convertible into 200,000 common stock shares), a $150,000 unsecured note and Mr. Fowler will remain on our health insurance plan. Mr. Fowler forgave $86,554 and may forgive up to $259,661 if the Company complies with the repayment plan.
Increased beneficial ownership percentage															9.99
Preferred stock shares issued												3,237			3,237					2,236
Preferred stock shares received												678,000			678,000
Outstanding debt															$ 2,559,000
Final payment					$ 750,000										750,000
Exchange agreement payment					$ 1,500,000
Dividends Paid Amount															$ 51,031
Forgive repayment amount							88,554
Series F-2 Convertible Preferred Shares | Maximum
Forgive repayment amount							$ 259,661
Series F-2 Convertible Preferred Shares | Mr. Blumberg
Shares exchange	88
Consulting fees	$ 88,000
Series F-2 Convertible Preferred Shares | Dr. Faupel
Shares exchange																					85
Long-term debt																					$ 85,000
Series F-2 Convertible Preferred Shares | Dr. Cartwright
Shares exchange																					100
Long-term debt																					$ 100,000
Series D Preferred Shares
Common stock, issued public shares												1,526,000		256,000	1,526,000
Preferred stock shares designated												6,000			6,000
Conversion price per share														$ 0.25	$ 0.25
Preferred stock shares converts into common stock														3,000	763
Liquidation preference												$ 763			$ 763
Increased beneficial ownership percentage															9.99
Preferred stock shares issued												763,000			763,000
Shares outstanding												763			763
Warrants for common stock shares equity														256,000
Warrant exercise price per share															0.25
Total investment amount														$ 128,000
Warrants to purchase common stock shares														256,000
Common stock warrants 1															1,526,000
Common stock warrants															1,526,000
Common stock warrants exercise price 1															$ 0.75
Related parties investment amount														$ 38,000
Warrants to purchase common stock shares exercise price														$ 0.75
Conversion of investor shares														128	3,000
Common stock issued during period															60,598
Preferred stock dividends accrued															$ 14,306
Common Stock primary trading shares exceed															1,000
Exceeds percentage															200.00%
Series E Preferred Shares
Preferred stock shares outstanding												1,736			1,736
Preferred stock shares designated												6,000			6,000
Conversion price per share															$ 0.25
Preferred stock shares converts into common stock															763			4,000
Liquidation preference												$ 1,736			$ 1,736
Preferred stock shares issued												1,736,000			1,736,000
Preferred stock shares received																	1,736
Dividends Paid Amount															$ 136,667
Total investment amount																	$ 1,735,500
Common Stock primary trading shares exceed															1,000
Exceeds percentage															200.00%
Equity investments fee																		$ 96,985
Increased election holder															9.99%
Conversion beneficial ownership limitation															4.99%
Maturity period															5 years
Incurred fees															$ 91,895
Cumulative dividends rate															8.00%
Series F and Series F-2 Preferred Shares
Preferred stock shares converts into common stock																	4,000
Preferred stock shares received																	2,114
Accrued Value												$ 136,667			$ 136,667
Series F Preferred Shares
Preferred stock shares outstanding												1,421			1,421
Preferred stock shares designated												1,500			1,500
Conversion price per share															$ 0.25
Preferred stock shares converts into common stock															4,000			4,000
Liquidation preference												$ 1,421			$ 1,421
Preferred stock shares issued												1,421			1,421
Common Stock primary trading shares exceed															1,000
Exceeds percentage															200.00%
Increased election holder															9.99%
Conversion beneficial ownership limitation															4.99%
Maturity period															5 years
Dividend amount												$ 22,659			$ 22,659
Cumulative dividend rate															6.00%
Accredited investors															$ 1,421,000

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - shares	Jul. 14, 2020	Jun. 30, 2021
STOCK OPTIONS
Stock options vested		892,977
Stock options unvested		932,023
Total stock options granted at June 30, 2021	1,800,000	1,825,000

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
STOCK OPTIONS
Outstanding at beginning of year | shares	1,800,000
Options granted | shares	25,000
Options exercised | shares	0
Options expired/forfeited | shares	0
Outstanding, end | shares	1,825,000
Options outstanding weighted average exercise price, beginning | $ / shares	$ 0.49
Options granted weighted average exercise price | $ / shares	0.49
Options exercised weighted average exercise price | $ / shares	0
Options expired/forfeited weighted average exercise price | $ / shares	0
Outstanding at end of the period | $ / shares	$ 0.49

STOCK OPTION (Details Narrative

STOCK OPTION (Details Narrative) - shares	Jul. 14, 2020	Jun. 30, 2021
STOCK OPTIONS
Stock options to employees and consultants	1,800,000	1,825,000
Stock options to employees and consultants term	10 years	10 years
Stock options granted outstanding common stock shares percentage	10.00%
Options granted exercisable term	4 years

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Jun. 30, 2021USD ($)
COMMITMENTS & CONTINGENCIES (Note 7)
2021	$ 62
2022	108
2023	112
2024	115
2025	118
Thereafter	50
Total	565
Less: interest	146
Present value of lease liability	$ 419

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

Mar. 10, 2021

Sep. 06, 2016

Jun. 05, 2016

Oct. 27, 2020

Jan. 22, 2020

Dec. 31, 2009

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2020

Mar. 31, 2021

Mar. 05, 2020

Jul. 24, 2019

Area of operating leases

12,835 square feet.

Right of use asset

$ 403,014

$ 403,014

Royalty percent

20

Licences

$ 1,000,000

sales

$ 4,000,000

Accrued Liability

$ 1,731,000

$ 1,731,000

$ 2,995,000

Common shares issued

13,296,880

13,296,880

13,138,282

13,180,417

Netl loss

$ (1,034,000)

$ (6,765,000)

$ (1,694,000)

$ (4,049,000)

Accumulated deficit

141,800,000

141,800,000

April 1, 2021 [Member]

Monthly rent

$ 8,824

April 1, 2022 [Member]

Monthly rent

9,091

April 1, 2023 [Member]

Monthly rent

9,370

April 1, 2024 [Member]

Monthly rent

9,648

April 1, 2025[Member]

Monthly rent

9,936

April 1, 2026 [Member]

Monthly rent

$ 10,236

Shandong Yaohua Medical Instrument Corporation [Member]

Accrued Liability

$ 692,335

Common shares issued

12,147

12,147

Shenghuo Medical, LLC [Member]

Payment receive descriptions

The right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million

Royalty Agreement [Member]

Royalty paid description

royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable that the Company sells (or that is sold by a third party pursuant to a licensing arrangement with the Company).

Royalty consideration

$ 50,000

Promotional Agreement [Member]

Consulting expenses

$ 397,222

Netl loss

$ (719,000)

Accumulated deficit

$ 140,200,000

Fair vaue of warrants

$ 715,000

Description of four tranches

the Company will issue a total of 5,000,000 warrants, broken into four tranches of 1,250,000. The warrants have a strike price of $0.25 and are subject to vesting based upon the close of the Series D offering and a minimum share price based on the 30-day VWAP.

Unrecognized consulting expense

$ 238,534

Mr. Blumberg | Consulting Agreement [Member]

Description of exchange of subscription

(1) on September 26, 2021, 900,000 3-year warrants with an exercise price of $0.30 and 400,000 common stock shares; (2) on March 26, 2022, 900,000 3-year warrants with an exercise price of $0.40 and 400,000 common stock shares; (3) on September 26, 2022, 900,000 3-year warrants with an exercise price of $0.50 and 400,000 common stock shares; and (4) on March 26, 2023, 900,000 3-year warrants with an exercise price of $0.60 and 400,000 common stock shares.

Subscription receivable

$ 350,000

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Notes payable in default, including related parties	$ 308	$ 329
Dr. Cartwright
Notes payable in default, including related parties	0	1
Mr. Fowler
Notes payable in default, including related parties	0	26
Mr. Mermelstein
Notes payable in default, including related parties	308	285
GPB
Notes payable in default, including related parties	$ 0	$ 17

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Short-term notes payable, including related parties	$ 65	$ 96
Dr. Cartwright
Short-term notes payable, including related parties	41	46
Dr. Faupel
Short-term notes payable, including related parties	5	5
Mr. Fowler
Short-term notes payable, including related parties	19	0
Premium Finance (Insurance)
Short-term notes payable, including related parties	$ 0	$ 45

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	Jul. 04, 2020	Mar. 22, 2021	Dec. 21, 2016	Jun. 30, 2021	Dec. 31, 2019	Feb. 19, 2021	Dec. 31, 2020	Jan. 19, 2017
Short-term notes payable				$ 65,000			$ 96,000
Extinguished of debt, Notes payable				1,808,712
Loss on extinguishment of debt				2,235,811
Short-term notes payable, including related parties others				65,000,000			96,000,000
Notes payable				$ 308,000			329,000
Annual interest rate description				The notes carry annual interest rates between 0% and 10% and have default rates as high as 20%. The Company is accruing interest at the default rate of 18.0% on loan to Mr. Mermelstein.
Notes payable in default, including related parties others				$ 308,000,000			329,000,000
Accrued interest				1,731,000			2,995,000
Premium Finance Agreement [Member]
Monthly payment of insurance	$ 11,299
Interest and mature description	4.968
Insurance policies	$ 109,000
Dr. Cartwright
Annual interest rate description					The notes were initially issued with 0% interest, however interest increased to 6.0% interest
Notes payable in default, including related parties others							1,000,000
Promissory notes issued				100,000	$ 41,000
Financing proceeds received by company					$ 1,000,000
Outstanding balance						$ 267,085	1,621,000
Mr. Fowler
Notes payable in default, including related parties others							26,000,000
Promissory notes issued			$ 26,400
Accrued interest								$ 18,718
Monthly payment of promisory notes		$ 3,580	$ 3,850
Outstanding balance				19,508
Dr. Faupel
Annual interest rate description					The notes were initially issued with 0% interest, however interest increased to 6.0% interest 90 days after
Promissory notes issued				85,000	$ 5,000
Financing proceeds received by company					$ 1,000,000
Outstanding balance						$ 153,178	$ 661,000
Troubled Debt Restructuring [Member]
Extinguished of debt, Notes payable				700,000
Loss on extinguishment of debt				29,000
Other expenses				$ 427,099

SHORTTERM CONVERTIBLE DEBT (Det

SHORTTERM CONVERTIBLE DEBT (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Convertible notes payable	$ 0	$ 1,930,000
Auctus Tranche Two [Member]
Convertible notes payable	400,000	400,000
Auctus Prepayment Penalty [Member]
Convertible notes payable	350,000	0
Auctus Tranche 1 [Member]
Convertible notes payable	0	700,000
Total Convertible Notes Payable
Convertible notes payable	720,000	951,000
Auctus
Convertible notes payable	0	113,000
Debt Discount and Issuance Costs to be Amortized
Convertible notes payable	$ 30,000	$ 262,000

SHORT-TERM CONVERTIBLE DEBT (De

SHORT-TERM CONVERTIBLE DEBT (Details Narrative) - USD ($)	Jan. 08, 2020	Jun. 05, 2016	Feb. 19, 2021	May 27, 2020	Mar. 23, 2020	Dec. 17, 2019	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Convertible notes payable							$ 0	$ 1,930,000
Common stock shares issued			2,236				7,957,013
Derivative liability							$ 29,000	25,000
Extinguishment of the derivative liability							1,808,712
Troubled Debt Restructuring [Member]
Prepayment penalty						$ 350,000	350,000
Extinguishment of the derivative liability							700,000
Loan							84,000
First Tranche [Member]
Warrants issued									7,500,000
Fair value of warrants						745,972
Warrant liability						635,000
Proceeds from warrant issued						635,000
Debt issuance cost						65,000
Administrative and legal expenses						570,000
Payment to convertible promissory note						89,250
Prepayment penalty						350,000	350,000	700,000
Accrued interest							73,889
Unamortized debt issuance costs							0	31,146
Unamortized debt discount on warrants							0	304,271
unamortized debt discount on warrants, balance							350,000	364,583
Convertible note received						$ 700,000
Rate of interest						percent (10%)
Description of matures						December 17, 2021
Outstanding balance of first two tranches							400,000	1,100,000
Second Tranche [Member]
Accrued interest							44,333	24,222
Unamortized debt issuance costs							30,336	47,086
unamortized debt discount on warrants, balance							369,664	$ 352,914
Convertible note received				$ 400,000
Rate of interest				ten percent (10%)
Description of matures				December 17, 2019
Derivative liability							$ 28,800
Warrant One [Member]
Warrants issued					496,602
Warrant Two [Member]
Warrants issued					692,446
Warrant Three [Member]
Warrants issued					692,446
Related Party Convertible Note Payable [Member]
Convertible notes payable									$ 512,719,000
Warrants issued					496,602
Cash investment		$ 200,000
Description of capital raising transactions		due upon consummation of any capital raising transaction by the Company within 90 days and with net cash proceeds of at least $1.0 million.
Distributor payment		$ 240,000
Conversion of debt outstanding	$ 790,544
Common stock shares issued					1,905,270
Short-term Convertible Notes Payable [Member]
Convertible note issued						$ 2,400,000

CONVERTIBLE DEBT IN DEFAULT (De

CONVERTIBLE DEBT IN DEFAULT (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Convertible Notes Past Due
Convertible notes in default	$ 169,000	$ 1,930,000
Auctus
Convertible notes in default	169,000	40,000
GPB
Convertible notes in default	0	1,709,000
GHS [Member]
Convertible notes in default	0	181,000
GHS [Member] | Note 1
Convertible notes in default	0	64,000
GHS [Member] | Note 2
Convertible notes in default	0	14,000
GHS [Member] | Note 3
Convertible notes in default	$ 90,000	$ 103,000

CONVERTIBLE DEBT IN DEFAULT (_2

CONVERTIBLE DEBT IN DEFAULT (Details Narrative) - USD ($)	Jun. 03, 2020	Dec. 07, 2016	Feb. 12, 2016	Feb. 19, 2021	Dec. 16, 2020	Jun. 30, 2020	May 22, 2020	Mar. 31, 2020	Mar. 20, 2018	May 19, 2017	May 28, 2016	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2021	Dec. 17, 2019	Dec. 31, 2018
Series F-2 Preferred Stock issued upon conversion of debt				2,236								7,957,013
Debt default outstanding balances												$ 168,561		$ 1,930,000
Accrued interest												$ 138,000		1,517,000
Exchangeable shares												0
Notes One [Member]
Notes payable							$ 150,000
Notes Two [Member]
Notes payable							89,250
Notes Three [Member]
Notes payable							65,000
Total Notes [Member]
Principal amount of promissory note														100,000
Outstanding balance of exchanged loans														40,000
Notes payable							328,422
Accrued interest and default penalty							160,000
Restricted common stock shares	500,000
Fair value of common shares							$ 196,818
Warrants issued							700,000
Troubled Debt Restructuring [Member]
Prepayment penalty												$ 350,000					$ 350,000
Convertible debt restructured												1,709,000
Auctus Fund, LLC [Member]
Default penalty												$ 112,750
Beneficial conversion feature																		$ 97,685
Interest rate												12.00%
Principal amount of promissory note														100,000
Warrant exercisable									4,262
Outstanding balance of exchanged loans														40,000
Issuance of promissory note						$ 250,000			$ 150,000
Exercise price						$ 0.16
Accrued expense												$ 16,656		10,260
Unamortized debt issuance costs												0		5,100
Convertible promissory note principal amount												112,750
Net proceeds												$ 100,000
Conversion rate												4.99%
Variable conversion price												55.00%
Note outstanding												$ 168,561
Default interest rate												24.00%
Default penalty amount												$ 55,811
Senior Secured Promissory Note
Accrued interest														1,233,637
Proceeds from debt				$ 1,029,000							$ 1,525,000
Original issue discount				257,500
Issuance of debt		$ 312,500		1,437,500							87,500
Debt issuance costs				$ 121,000
Principal amount of promissory note		1,837,500												1,362,384
Royalty payment, payable quarterly			3.85
Royaltiy													$ 35,000
Convertible debt														1,709,414
Prepayment penalty														$ 347,030
Cash placement fee description														For its services, the placement agent received a cash placement fee equal to 4% of the aggregate gross proceeds from the transaction and a warrant to purchase shares of common stock equal to an aggregate of 6% of the total number of shares underlying the securities sold in the transaction
GPB
Series F-2 Preferred Stock issued upon conversion of debt								2,236
Accrued interest														$ 17,816
Default penalty														37,926
Outstanding debt balance														63,520
Proceeds from debt										$ 66,000
Convertible promissory note										66,000
Original issue discount										$ 6,000
Conversion price description										the Company’s stock at a conversion price equal to 60% of the lowest trading price during the 25 trading days prior to conversion.
Interest rate										8.00%
Repayment of debt					$ 25,000
Debt instrument converted amount															$ 12,700
Adusted warrant price																$ 0.20
Exchangeable shares								7,185,000
Issuance of debt		$ 312,500									$ 87,500
GPB | Share-based Payment Arrangement, Tranche One [Member]
Repayment of debt								$ 450,000
GPB | Share-based Payment Arrangement, Tranche Two [Member]
Repayment of debt								100,000
GPB | Share-based Payment Arrangement, Tranche Three [Member]
Repayment of debt								950,000
May 17, 2018 [Member] | GHS [Member]
Accrued interest														5,006
Default penalty														4,937
Outstanding debt balance														14,187
Proceeds from debt													$ 7,500
Convertible promissory note												9,250
Original issue discount												750
Debt issuance costs												1,000
Conversion price description													The note accrued interest at a rate of 8% per year until its matured June 17, 2019.
June 22, 2018 [Member] | GHS [Member]
Accrued interest												0		39,644
Default penalty														35,285
Outstanding debt balance														$ 103,285
Proceeds from debt													$ 68,000
Convertible promissory note												68,000
Original issue discount												2,000
Debt issuance costs												6,000
Conversion price description													The accrued interest at a rate of 10% per year until it matured on June 22, 2019.
Beneficial conversion feature												$ 29,143
September 2, 2020 [Member]
Repayment of debt								150,000
Forbearance amount								$ 50,000

LONG TERM DEBT (Details 1)

LONG TERM DEBT (Details 1) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Total	$ 755	$ 23
Long-Term Debt - Related Parties | Mr. Fowler
2021	0
2022	0
2023	462
2024	43
2025	43
Thereafter	31
Total	$ 579

LONG TERM DEBT (Details)

LONG TERM DEBT (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Feb. 19, 2021
Bonus	$ 781,000	$ 1,094,000
Vacation	43,000	34,000
Dr. Cartwright
Salary		337,000
Bonus		675,000
Interest on compensation		528,000
Loans to Company		196,000
Interest on loans		149,000
Total outstanding prior to exchange		1,621,000		$ 267,085
Amount forgiven		(1,302,000)
Total interest accrued		45,000
Exchange for Series F-2 Preferred Stock	(100,000)		$ (41,000)
Interest accrued	7,000
Balance outstanding, end of period	271,000	364,000
Dr. Faupel
Salary		134,000
Bonus		20,000
Interest on compensation		67,000
Loans to Company		196,000
Interest on loans		149,000
Total outstanding prior to exchange		661,000		$ 153,178
Amount forgiven		(454,000)
Total interest accrued		29,000
Exchange for Series F-2 Preferred Stock	(85,000)		$ (5,000)
Interest accrued	7,000
Balance outstanding, end of period	$ 158,000	236,000
Vacation		$ 95,000

LONG TERM DEBT (Details Narrati

LONG TERM DEBT (Details Narrative) - USD ($)	May 04, 2020	May 17, 2021	Mar. 22, 2021	Feb. 19, 2021	Dec. 21, 2016	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2018	Sep. 30, 2018	Sep. 04, 2018
Long-term debt-related parties						$ 579,000
Gain for extinguishment of debt						185,000	$ 316,000
Accrued interest						$ 138,000		$ 1,517,000
Series F-2 Preferred Stock issued upon conversion of debt				2,236		7,957,013
Current portion of long-term debt						$ 24,000		28,000
Paycheck Protection Program
Accrued interest						331		293
Debt forgiveness amount							23,742
Proceeds from loan	$ 50,184
Loan interest rate	1.00
Loan maturity term	24
Payroll costs	$ 100,000
Current portion of long-term debt						24,331		50,477
Debt interest forgiveness amount							234
10% Senior Unsecured Convertible Debenture
Accrued interest						14,103		293
Debt maturity date		May 17, 2024
Proceeds from convertible debenture		$ 1,130,000
Convertible debentures		$ 1,000				1,130,000
Conversion price		$ 0.50
Convertible debentures right description		each debenture unit will have a right to 1,000 warrants for common stock shares, warrants have an exercise price of $0.80 and an expiration date of May 17, 2023; 4)
Change of Control premium percentage		3
Deemed price		$ 0.50
Bond payable discount						375,000
Convertible debentures net of discount						755,000
Unamortized debt issuance costs						83,520
Debt issuance costs							$ 341,597
Dr. Cartwright
Long-term debt-related parties						271,000
Total outstanding prior to exchange				$ 267,085				1,621,000
Due to related party											$ 1,621,000
Issuance of promissory note in exchange of related party debt											319,000
Gain for extinguishment of debt									$ 840,000
Capital contribution									432,000
Accrued interest									30,000
Promissory note maturity date				February 18, 2023
Promissory note interest rate				6
Debt instrument converted amount				$ 85,000
Series F-2 Preferred Stock issued upon conversion of debt				100
Debt forgiveness amount								1,302,000
Mr. Fowler
Long-term debt-related parties						150,000
Total outstanding prior to exchange						19,508
Due to related party			$ 546,214
Accrued interest			$ 133,590
Promissory note interest rate			6
Debt instrument converted amount			$ 50,000
Series F-2 Preferred Stock issued upon conversion of debt			50
Series F-2 Preferred Shares conversion description			Series F-2 Preferred Shares (convertible into 200,000 common stock shares), and a $150,000 unsecured note and Mr. Fowler remains on the Company’s health insurance plan.
Promissory note default interest rate			18
Promissory note monthly installment			$ 3,580		$ 3,850
Effective interest rate			3.0
Deferred salary			$ 412,624
Unsecured note issued upon conversion of debt			150,000
Mr. Fowler | Long-Term Debt - Related Parties
Total outstanding prior to exchange			26,400
Accrued interest			18,718
Debt forgiveness amount			$ 86,554
Debt forgiveness description			may forgive up to $259,661 if the Company complies with the repayment plan described above.
Dr. Faupel and Mr. Cartwright [Member] | July 24, 2019 [Member]
Simple interest rate							6
Debt maturity description							the principal and accrued interest due in total at the date of maturity or February 18, 2023.
Dr. Faupel
Long-term debt-related parties						$ 158,000
Total outstanding prior to exchange				$ 153,178				661,000
Due to related party										$ 661,000	661,000
Issuance of promissory note in exchange of related party debt											$ 207,000
Gain for extinguishment of debt									199,000
Capital contribution									235,000
Accrued interest									$ 20,000
Promissory note maturity date				February 18, 2023
Promissory note interest rate				6
Debt instrument converted amount				$ 100,000
Series F-2 Preferred Stock issued upon conversion of debt				85
Debt forgiveness amount								$ 454,000

INCOME (LOSS) PER COMMON SHAR_2

INCOME (LOSS) PER COMMON SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net loss	$ (1,159)	$ (6,766)	$ (1,871)	$ (4,049)
Basic weighted average number of shares outstanding			13,226	8,463
Net loss per share (basic)			$ (0.14)	$ (0.48)
Diluted weighted average number of shares outstanding			13,172	8,463
Net loss per share (diluted)			$ (0.14)	$ (0.48)
Dilutive equity instruments (number of equivalent units)			37,466	36,569
Warrants [Member]
Dilutive equity instruments (number of equivalent units)			17,869	4,341
Convertible Debt [Member]
Dilutive equity instruments (number of equivalent units)			1,281	31,228
Preferred Stock [Member]
Dilutive equity instruments (number of equivalent units)			18,316	0
Equity Option [Member]
Dilutive equity instruments (number of equivalent units)			0	0

INCOME (LOSS) PER COMMON SHAR_3

INCOME (LOSS) PER COMMON SHARE (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
INCOME (LOSS) PER COMMON SHARE
Troubled debt restructuring		$ 179,000
Troubled debt restructuring description	the troubled debt restructuring in total would have decreased the net loss by $296,000 and causing the per share calculation to change from .04 to .06.

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - July 22, 2021 [Member]	6 Months Ended
	Jun. 30, 2021
Reverse split description	1-for-20,
Series F Preferred Stock [Member]
Amendment to the Certificate of Incorporation description	the adoption of an amendment to the Company’s Certificate of Designation of the Series F preferred stock to increase the number of authorized shares from 1,500 to 4,000 with such increase to be determined at the sole discretion of the Board and with such increase to be effected at such time and date on or before December 31, 2021,
Common Stock [Member]
Amendment to the Certificate of Incorporation description	the adoption of an amendment to the Certificate of Incorporation, to, among other things, decrease the Company’s authorized common stock from 3,000,000,000 shares to 500,000,000 shares (the “Charter Proposal”);